Cytomegalovirus restricts ICOSL expression on antigen presenting cells disabling T cell costimulation and contributing to immune evasion

Angulo, Guillem; Železnjak, Jelena; Martínez-Vicente, Pablo; Puñet-Ortiz, Joan; Hengel, Hartmut; Messerle, Martin; Oxenius, Annette; Jonjić, Stipan; Krmpotić, Astrid; Engel, Pablo; ...

Source / Izvornik: eLife, 2021, 10

Journal article, Accepted version Rad u časopisu, Završna verzija rukopisa prihvaćena za objavljivanje (postprint)

https://doi.org/10.7554/eLife.59350

Permanent link / Trajna poveznica: https://urn.nsk.hr/urn:nbn:hr:184:503816

Rights / Prava: <u>Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0</u> međunarodna

Download date / Datum preuzimanja: 2025-03-11



Repository / Repozitorij:

Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository





1	Cytomegalovirus restricts ICOSL expression on antigen presenting
2	cells disabling T cell co-stimulation and contributing to immune
3	evasion
4	
5	Guillem Angulo ^{1†} , Jelena Zeleznjak ^{2,3†} , Pablo Martínez-Vicente ^{1,4} , Joan Puñet-Ortiz ^{1,4} ,
6	Hartmut Hengel ^{5,6} , Martin Messerle ⁷ , Annette Oxenius ⁸ , Stipan Jonjic ^{2,3} , Astrid
7	Krmpotić ³ , Pablo Engel ^{1,4} , and Ana Angulo ^{1,4*}
8	
9	¹ Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and
10	Health Sciences, University of Barcelona, Barcelona 08036, Spain
11	² Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka 51000,
12	Croatia
13	³ Department of Histology and Embryology, Faculty of Medicine, University of Rijeka,
14	Rijeka 51000, Croatia
15	⁴ Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona 08036, Spain
16	⁵ Institute of Virology, University Medical Center, Albert-Ludwigs-University Freiburg,
17	79104 Freiburg, Germany
18	⁶ Faculty of Medicine, Albert-Ludwigs-University Freiburg, 79104 Freiburg, Germany
19	⁷ Institute of Virology, Hannover Medical School, Hannover 30625, Germany
20	⁸ Institute of Microbiology, Department of Biology, ETH Zürich, Zürich, Switzerland
21	*Corresponding author: <u>aangulo@ub.edu</u>
22	⁺ These authors contributed equally to this work
23	Short Title: MCMV decreases T-cell activation by downregulating ICOSL expression

24 Abstract

25

Viral infections are controlled, and very often cleared, by activated T lymphocytes. The 26 inducible co-stimulator (ICOS) mediates its functions by binding to its ligand ICOSL, 27 enhancing T-cell activation and optimal germinal center (GC) formation. Here, we show 28 that ICOSL is heavily downmodulated during infection of antigen presenting cells by 29 30 different herpesviruses. We found that, in murine cytomegalovirus (MCMV), the immunoevasin m138/fcr-1 physically interacts with ICOSL, impeding its maturation 31 and promoting its lysosomal degradation. This viral protein counteracts T-cell 32 responses, in an ICOS-dependent manner, and limits virus control during the acute 33 MCMV infection. Additionally, we report that blockade of ICOSL in MCMV-infected 34 mice critically regulates the production of MCMV-specific antibodies due to a reduction 35 of T follicular helper and GC B cells. Altogether, these findings reveal a novel 36 mechanism evolved by MCMV to counteract adaptive immune surveillance, and 37 38 demonstrates a role of the ICOS:ICOSL axis in the host defense against herpesviruses.

39 Introduction

40

41 A robust host response against viral infections requires the activation of the adaptive 42 arm of the immune system mediated by T lymphocytes. For effective T-cell activation, in addition to the antigen-specific signal delivered by the interaction of major 43 44 histocompatibility (MHC)-peptide complexes and T-cell receptors (TCR), concerted costimulatory signals are essential. These signals come from a number of co-stimulatory 45 molecules upon interaction with their cognate ligands, expressed on antigen-presenting 46 47 cells (APCs) (Sharpe, 2009; Chen and Flies, 2013). The B7-CD28 family of ligands and receptors comprises molecules of the Ig superfamily that function as co-signaling 48 molecules modulating T-cell responses (Sharpe and Freeman, 2002). The best 49 50 characterized co-stimulatory pathway between members of this family is exemplified by the T-cell surface receptor CD28, which binds to the activated APC surface molecules 51 B7-1 (CD80) and B7-2 (CD86). Another co-stimulatory pathway of this family is the 52 receptor ICOS (inducible co-stimulator, CD278), primarily expressed on activated T 53 cells and at very high levels on T follicular helper cells (Tfh), which mediates its 54 55 functions by binding to its ligand ICOSL (B7-H2, CD275) (Hutloff et al., 1999; Yoshinaga et al., 1999). ICOSL is constitutively expressed on APCs, such as dendritic 56 57 cells (DCs), macrophages and B cells, and it is strongly up-regulated by inflammatory 58 stimuli (Aicher et al., 2000; Swallow et al., 1999; Yoshinaga et al., 2000). ICOSL presents a different expression profile as compared to CD80 and CD86, and it is 59 induced on non-lymphoid cells, such as endothelial cells or epithelial cells 60 (Khayyamian et al., 2002; Qian et al., 2006). The ICOS: ICOSL receptor pathway leads 61 62 to enhanced T-cell activation, proliferation, and Th2 responses (Riley et al., 2002; Tesciuba et al., 2001). In contrast to CD28, which is essential for the activation of 63

naïve T cells, ICOS is more relevant for the regulation of activated and effector T cells 64 65 (Coyle et al., 2000). In addition, ICOS co-stimulation plays an essential role in Tdependent antibody responses and germinal center (GC) formation, by inducing IL-21 66 67 production and Bcl6 expression, consequently controlling isotype switching, somatic hypermutation, and the generation of memory B cells and plasma cells (Choi et al., 68 2011; Hutloff, 2015; Liu et al., 2015). ICOS has also been shown to be required for 69 70 optimal CD8⁺ T-cell proliferation and cytokine production during recall responses (Takahashi et al., 2009; Wallin et al., 2001) and NK cell activation (Ogasawara et al., 71 2002). Importantly, although the ICOSL:ICOS axis is a crucial tuner of cell-mediated 72 73 immune responses, little is known about its role in viral host defence.

74

75 Throughout the process of pathogen-host coevolution, viruses have devised multiple 76 strategies to counteract host immunity. In particular, in order to ensure their prolonged survival in their hosts, persistent viruses need to undermine adaptive immune responses 77 78 at different levels. A common theme of these viruses is to interfere with the presentation of antigenic peptides by MHC molecules to T cells. To this end, several large DNA 79 viruses, particularly herpesviruses, encode multiple proteins, which usually are not 80 81 essential for replication *in vitro*, with the capacity to interfere with the MHC molecules or additional cellular components involved in antigen presentation pathway (Schuren et 82 al., 2016). Given the importance of APCs in triggering and maintenance of adaptive 83 antiviral immune responses, herpesviruses have evolved molecular determinants and 84 mechanisms to impair their functions (Brinkmann et al., 2015; Gewurz et al., 2007). 85 Among them, different members of the herpesvirus family have been reported to disrupt 86 the interaction established by co-signaling molecules in infected APCs and their counter 87 receptors, in particular by downregulating CD80 and CD86. This is the case for 88

4

example of the human and murine cytomegaloviruses (HCMV and MCMV, respectively), which cause the downregulation of these two molecules during their respective infectious courses (Hertel et al., 2003; Loewendorf et al., 2004; Mintern et al., 2006; Moutaftsi et al., 2002). However, whether viruses have evolved immune evasion strategies to counteract the ICOSL:ICOS pathway remains largely unexplored.

94

95 Here we report that ICOSL-mediated co-stimulation contributes to the development of 96 effective anti-MCMV immune responses. In addition, we demonstrate that ICOSL 97 constitutes a major target of CMVs and other herpesviruses, which potently 98 downregulate its expression on the surface of APCs. We show that MCMV uses its 99 immunoevasin m138/fcr-1 to manipulate this co-signaling molecule, impeding a 100 correct T-cell activation during acute MCMV infection. These results reveal a new 101 mechanism of viral immune evasion. 102 **Results**

103

104 MCMV infection rapidly induces a potent ICOSL downregulation in APCs

105 ICOSL is constitutively expressed at high levels on APCs, including DCs and macrophages, which are cell types that are susceptible to MCMV infection. In order to 106 evaluate whether MCMV has the capacity to alter cell-surface expression of ICOSL, we 107 108 initially mock-infected or infected murine peritoneal macrophages, at a multiplicity of 109 infection (moi) of 10, with a GFP expressing MCMV (MCMV-GFP). Under these conditions, around 50% of the cells in the culture were infected. Three days later, 110 cultures were analyzed by flow cytometry to measure the expression of cell surface 111 ICOSL. At this time point, as expected, the density of MHC I at the cell surface was 112 113 strongly reduced (Figure 1A). Notably, a pronounced downmodulation of ICOSL was also observed in GFP+ infected cells as compared with uninfected GFP- cells from the 114 115 same cultures, or with mock-infected samples (Figure 1A). Indeed, ICOSL levels 116 decreased to almost undetectable levels, whereas the expression of the adhesion molecule CD62L, used as a negative control, remained unaffected. We next assessed if 117 these findings could be extended to primary bone-marrow-derived macrophages (BMM) 118 119 and dendritic cells (BMDC). Importantly, while robust expression of ICOSL was observed on all uninfected (mock or GFP-) cells, the surface reduction of this molecule 120 121 in MCMV infected BMMs and BMDCs was significant (Figure 1B). Similar results were also obtained upon infection of the macrophage cell line IC-21, the dendritic cell 122 line DC2.4, and the endothelial cell line SVEC4-10, although the extent of 123 124 downregulation differed between them (Figure 1B), being quite dramatic on the IC-21 and DC2.4 cells, and more subtle in the SVEC4-10. Altogether, these findings 125

demonstrate that MCMV infection causes a consistent and specific downmodulation ofICOSL from the surface of APCs.

We then assessed whether *de novo* viral protein synthesis was required for ICOSL 128 129 downregulation. To this end, peritoneal macrophages were infected for 72 h (infection rates, approximately 90%) with UV-inactivated MCMV, and the results showed no loss 130 of ICOSL surface expression (Figure 1C), indicating that a productive MCMV infection 131 132 was required to alter ICOSL expression. To determine the kinetics of ICOSL downmodulation, we examined its surface expression levels at different time points 133 following infection of peritoneal macrophages with MCMV-GFP. As shown in Figure 134 135 1D, by 4 hours post infection (hpi) the density of ICOSL at the cell surface was substantially reduced, and by 6 hpi there was barely any ICOSL at the surface of 136 infected cells. When a similar kinetics was conducted in BMDC and IC-21 cells, the 137 downregulation of ICOSL differed with respect to timing, beginning to be evident by 8 138 hpi and 16 hpi, respectively, with the effect becoming more prominent from that time 139 140 point onwards. Thus, we concluded that MCMV encodes one or more proteins to 141 rapidly lower cell surface levels of ICOSL upon infection of APCs.

142

143 The MCMV m138 gene is responsible for ICOSL downmodulation

In order to find the viral gene/s mediating the observed effects on ICOSL expression, we screened a panel of GFP-expressing MCMV deletion mutants that lack different regions of the viral genome, and which covered a large number of genes dispensable for viral replication in cell culture. The levels of ICOSL were monitored by flow cytometry three days after infection of IC-21 cells with the different mutants. We found that, except for the deletion mutant MCMV Δ m128-138, all MCMV mutants tested resulted in the marked downmodulation of ICOSL expression (Figure 2A; see as an example 151 results for the MCMV Δ m1-17 mutant). The viral region deleted in MCMV Δ m128-138, expanding from ORF m128 to m138, includes some ORFs with functions still 152 153 unassigned and others involved in viral-host interactions, such as the m129/m131 154 chemokine homolog associated with tropism to macrophages (Fleming et al., 1999; 155 Stahl et al., 2015), or the m138 protein, originally described as an Fc receptor (Thäle et 156 al., 1994), and later reported to be also implicated in the reduction of cell surface expression of the NKG2D ligands H60, MULT-1, and RAE-1ɛ (Arapović et al., 2009; 157 158 Lenac et al., 2006), and interestingly, of the co-stimulatory molecule CD80 (Mintern et 159 al., 2006), a member of the B7 family to which also ICOSL belongs. Based on this later 160 feature of m138 and the fact that the viral protein is expressed early during infection, we speculated that the gene altering ICOSL expression in MCMV infected cells might be 161 162 m138. To directly test the hypothesis, we used an MCMV with a deletion in this gene (MCMV∆m138). As illustrated in Figure 2B, during infection of IC-21 cells with 163 MCMV∆m138, cell surface expression of ICOSL was maintained to levels similar to 164 mock-infected cells, while the levels of CD84, a molecule targeted by the MCMV m154 165 166 protein (Strazic et al., 2020), used as a control markedly decreased. These effects were 167 not due to a growth defect of the mutant virus in IC-21 cells, as indicated in earlier 168 studies where comparable multi-step growth kinetics between an MCMV deleted in 169 m137-m139 and parental MCMV were observed (Cavanaugh et al., 1996). These results 170 revealed that one gene product, m138, is responsible for the complete downregulation 171 of ICOSL during MCMV infection.

We next asked if m138, in the absence of other viral molecules, was sufficient to decrease cell surface levels of ICOSL. To this end, we cloned the m138 gene fused at the C-terminus with the GFP protein and used the resulting recombinant plasmid (named m138-GFP) or the parental GFP only-expressing plasmid (CTL-GFP) to

8

176 transiently transfect IC-21 cells. Flow cytometry analysis 24 hours after transfection 177 showed that cells transfected with the m138-expressing construct (GFP+) exhibited a significant reduction of ICOSL surface expression compared to the untransfected 178 179 control cells from the same cultures or mock-transfected cells (GFP-; Figure 2C, left panel). In contrast, we could not detect any change in the expression of ICOSL in cells 180 181 transfected with the GFP only-expressing plasmid (compare GFP+ and GFP- cells in 182 Figure 2C, right panel). Therefore, these results indicate that m138 is able to exert its downmodulatory effects on ICOSL expression without requiring the MCMV infection 183 context. 184

185

186 Localization of m138 during MCMV infection

187 m138 has been predicted to be a 569-aa type I transmembrane glycoprotein (Thäle et al., 188 1994). Due to the lack of an m138 monoclonal antibody (mAb), the cellular localization of this viral protein during MCMV infection has so far not been directly assessed. 189 190 Previous studies relied on cells expressing the m138 protein in isolation, or on the 191 different capacity displayed by cells infected with MCMV or with an MCMV mutant lacking the viral protein to bind Ig. Thus, in order to detect m138 in the infection 192 context, we generated a mAb specific for m138, using 300.19 cells stably transfected 193 with the m138 protein HA-tagged at the N-terminus (HA-m138) as immunogen. Then, 194 195 NIH3T3 cells were infected with MCMV-GFP, and m138 expression was analyzed by 196 indirect immunofluorescence employing this newly generated mAb. As shown in Figure 3A (panels a-c and g), using permeabilizing conditions, the viral protein was detected in 197 perinuclear compartments and cytoplasmic "large punctate vesicles" in GFP+ infected 198 cells. Similar results were obtained in MCMV-GFP infected DC2.4 cells (Figure 3-199 figure supplement 1). Therefore, these results were consistent with earlier reports in 200

201 transfected cells, showing the m138 protein being mainly expressed in intracellular 202 compartments together with markers of the ER, protein disulfide isomerase-A1 (PDI) and calnexin, in addition with the lysosomal marker LAMP-1 (Mintern et al., 2006; 203 204 Thäle et al., 1994). In contrast, in non-permeabilized infected cells, the mAb against m138 failed to detect the viral protein at the cell surface (Figure 3A, panels d-f), 205 206 whereas it could be recognized at this location in the 300.19 cells stably transfected with 207 HA-m138 (Figure 3C, left panels). When analyzed by flow cytometry, though, a dim expression of m138 at the cell surface of infected cells could be observed (Figure 3B). 208 As expected, the viral protein was also strongly recognized at the plasma membrane of 209 210 the transfected cell when assessed by flow cytometry (Figure 3C, right panel). Finally, to evaluate whether m138 could be found in lysosomes, NIH3T3 cells were infected 211 212 with MCMVwt for 24 h and stained with LysoTracker Red DND99, a fluorescent 213 marker that labels acidic components and is employed to identify lysosomes. Infected 214 cells were then analyzed by immunofluorescence using the m138 specific mAb under 215 gently permeabilizing conditions (0.02% saponin) to preserve the LysoTracker staining. 216 The results, illustrated in Figure 3D (panels c, and d), indicated that m138 colocalized with lysosomes. Indeed, quantification of the m138/lysosome colocalization, using the 217 218 Coloc2 plugin from FIJI/ImageJ program, led to Manders colocalization coefficients of M1=0.76 and M2=0.80. 219

220

m138 prevents ICOSL molecules from reaching the plasma membrane via targeting to lysosomal degradation

We next sought to study the mechanism by which m138 downregulates ICOSL. Since there are no available antibodies capable to detect murine ICOSL in western blot, we generated an NIH3T3 stable cell line expressing HA-ICOSL. We confirmed by flow

cytometry that upon infection with MCMVwt, or following transient transfection with 226 the plasmid expressing GFP tagged m138, but not after infection with MCMV∆m138, 227 228 HA-ICOSL levels specifically declined at the plasma membrane of the stable HA-ICOSL expressing cell line (Figure 4A and B). NIH3T3 HA-ICOSL cells were then 229 mock-infected or infected with MCMVwt or MCMVAm138, lysates prepared and 230 231 western blots performed to examine total ICOSL protein levels by staining for the HA tag. As shown in Figure 4C, two ICOSL specific bands, with apparent molecular masses 232 of ~ 51 and 70 kDa, were detected in the HA-ICOSL stable cell line as compared to 233 234 untransfected NIH3T3 cells (compare lanes 1 and 2). Notably, in MCMV infected cell 235 lysates, the 70 kDa band was drastically reduced (lane 4), whereas it was not 236 substantially altered after infection with MCMVAm138 (lane 5), suggesting that this band corresponds to the mature surface form of ICOSL. Indeed, a mild treatment of the 237 NIH3T3 HA-ICOSL cells with trypsin, which selectively cleaves the ectodomains of 238 239 molecules at the cell surface, and therefore resulted in the loss of detection of ICOSL when assessed by flow cytometry (Figure 4D), led to the disappearance of the 70 kDa 240 241 band in the western blot (Figure 4C, lane 3). Further demonstration that the larger 242 ICOSL species corresponded to the one present at the cell surface was obtained from a 243 parallel experiment in which we immunoprecipitated lysates from biotinylated HA-ICOSL transfected cells with the anti-HA mAb (Figure 4E). Thus, m138 was altering 244 245 the expression of the mature form of ICOSL that reaches the cell surface. In addition, we noted, that the 51 kDa band was more abundantly expressed in the infected samples 246 247 than in the mock-infected samples (Figure 4C, compare lanes 2 with lanes 4 and 5). The fact that ICOSL was slightly induced at the cell surface after treatment with UV-248 249 inactivated MCMV (Figure 1C), could indicate that virion components or the process of 250 viral binding may be causing these effects. Supporting this observation, an analysis of

extracts from NIH3T3 HA-ICOSL cells infected with UV-inactivated MCMV indicated
that this was the case, with both the 51 kDa and the 70 kDa bands being considerably
more abundant than in the mock-infected samples (Figure 4F, compare lanes 2 and 4).
Thus, MCMV infection initially induces ICOSL expression and m138 subsequently
leads to the depletion of cell-surface ICOSL, but not of the overall intracellular levels of
this molecule.

257 Taking into account the intracellular localization of m138 and the fact that it targets the B7 costimulatory molecule CD80 early in the secretory pathway, rerouting it to 258 lysosomes, we contemplated the possibility that the viral protein was behaving in a 259 260 similar way to interfere with ICOSL (Mintern et al., 2006). We addressed this issue by co-transfecting NIH3T3 cells with the plasmid encoding for HA-ICOSL together with 261 262 either the construct expressing m138-GFP or an unrelated GFP protein (CTL-GFP), and 263 analyzing the levels of ICOSL expression by western blot before and after treatment with a combination of two lysosomal inhibitors, leupeptin and bafilomycin. Under these 264 265 transient transfection conditions, and in contrast to the assays in stably transfected NIH3T3 HA-ICOSL cells, ICOSL and m138 were simultaneously expressed, without 266 previous existence of ICOSL at the cell surface. As shown in Figure 5A, in cells co-267 268 transfected with the m138-GFP protein, independently of whether or not the lysosomal inhibitor treatment was applied, the 70 kDa ICOSL band, corresponding to ICOSL on 269 the cell surface, was not observed (lanes 4 and 5). In addition, the results also evidenced 270 271 that the 51 kDa band, corresponding to intracellular ICOSL, augmented (1.5-fold) after exposure to leupeptin and bafilomycin (compare lanes 4 and 5). In contrast, in cells 272 expressing the CTL-GFP protein, both the 51 and 70 kDa bands were present, and the 273 blockade of the lysosomal pathway did not lead to a substantial alteration (1.1-fold) of 274 any of the two ICOSL forms (Figure 5A, compare lanes 2 and 3). The presence of the 275

70 kDa mature form of ICOSL when the CTL-GFP was expressed, and its absence upon 276 277 expression of m138-GFP under conditions of lysosomal inhibition, pointed out that the viral protein was targeting ICOSL before reaching the cell surface. We then infected 278 279 NIH3T3 HA-ICOSL cells with MCMVwt and examined by confocal fluorescence microscopy m138 and ICOSL expression. A marked colocalization of ICOSL and the 280 281 viral protein in perinuclear compartments and in cytoplasmic punctate structures could 282 be observed, being more robust after treatment with the lysosomal inhibitors (Figure 5B, panels g and h). Accordingly, the expression signal of ICOSL was also increased 283 after treatment with leupeptin and bafilomycin (compare panels a and e in Figure 5B). 284 285 The results also showed augmented levels of m138 upon exposure to the lysosomal inhibitors (compare panels b and f), indicating that m138 was getting partially co-286 287 degraded with its target. These observations were confirmed by flow cytometry in 288 permeabilized NIH3T3 HA-ICOSL MCMV-infected cells, where significant higher levels of expression of both ICOSL and m138 could be detected after blockade of the 289 290 lysosomal pathway (Figure 5C). Collectively, the data suggest that m138 precludes the 291 maturation of ICOSL by targeting it to lysosomes, explaining how the levels of this cosignaling molecule are decreased at the cell surface. 292

293

294 m138 interacts with ICOSL

We then considered the possibility that m138 might be interacting with ICOSL, as it has been previously shown for CD80. To this end, we performed coimmunoprecipitation assays using NIH3T3 cells transiently expressing m138-GFP and HA-ICOSL. Proteins were pulled down by an anti-HA antibody and analyzed by western blot using an antibody against GFP. Taking into account the potential capacity of m138 to bind IgG, an immunoprecipitation was carried out with an anti-human Fc antibody as a control. As illustrated in Figure 5D, the m138 protein was recovered when the immunoprecipitation was carried out with the anti-HA antibody (lane 2), whereas when using the antibody against human Fc the viral protein was not detected (lane 1). As expected, after stripping the western blot and reprobing it with an anti-HA antibody, the 51 kDa specific ICOSL band was only observed in the precipitates obtained from the anti-HA mAb pull downs. These data suggest that m138, either directly or in an indirect manner, associates with ICOSL.

308

309 Distinct m138 structural domains are required to downmodulate the two members 310 of the B7 family, ICOSL and CD80

The ectodomain of m138 is predicted to be composed by three Ig-like domains (Lenac 311 et al., 2006; Corrales -Aguilar et al., 2014). Previous work using mutant MCMVs 312 313 containing m138 versions defective in either three potential Ig-like domains indicated different structural requirements in this viral protein for the downregulation of the 314 315 NKG2D ligands (Lenac et al., 2006). We investigated if this was also the case for m138 316 to exert its effects on the two co-stimulatory molecules ICOSL and CD80, since this 317 could allow us to dissect the impact of the viral protein on the two pathways of T-cell 318 activation. Thus, we created three different m138-GFP mutants, missing the putative Nterminal Ig domain (Ig1; m138 Δ Ig1-GFP), the middle Ig domain (Ig2; m138 Δ Ig2-GFP), 319 or both the middle and membrane-proximal (Ig3) Ig domains (m138AIg2/3-GFP) 320 (Figure 6A, schematic representation of these constructs). Each m138-GFP mutant 321 322 construct was transiently expressed on NIH3T3 HA-ICOSL cells and surface levels of 323 ICOSL and CD80 were assessed by flow cytometry and compared to those present in 324 cells transfected with the m138-GFP control. As shown in Figure 6B, the m138∆Ig1-GFP protein was incapable to significantly reduce ICOSL or CD80 cell surface levels. 325

In contrast, while CD80 surface density decreased in cells transfected with m138 Δ Ig2-GFP and m138 Δ Ig2/3-GFP, these two m138 mutants did not alter in a substantial manner ICOSL expression. Therefore, we conclude that the Ig1 domain of m138 is absolutely required for both ICOSL and CD80 downregulation. However, while the putative Ig2 and Ig3 domains of m138 need to be preserved for the downregulation of ICOSL, they are dispensable for m138-mediated decrease of CD80 expression.

332

m138 curtails ICOSL-dependent antigen presentation and subsequent CD8⁺ T-cell responses during MCMV infection of APCs

The differential structural requirements of m138 to target CD80 and ICOSL permitted 335 us to specifically address the functional consequences of the disruption of the 336 337 ICOSL: ICOS pathway during the course of the MCMV infection. To this end, we employed two MCMV mutants containing m138 versions lacking either the Ig2 domain 338 339 (MCMVm138AIg2), or the Ig2 and Ig3 domains (MCMVm138AIg2/Ig3). As it occurred in transfection assays with the m138 mutant plasmids defective in these Ig 340 domains, infections with MCMVm138AIg2 or MCMVm138AIg2/Ig3 led to decreased 341 cell-surface density of CD80 but not ICOSL (Figure 7A). We then performed an in vitro 342 343 antigen presentation assay assessing the effect of these two MCMV mutants on the ability of APCs to induce an ICOSL-dependent CD8⁺ T-cell response, in comparison to 344 345 that of MCMVwt and MCMV∆m138. We co-cultivated BMDCs infected with the different viruses with naive CD8⁺ T cells from splenocytes derived from T-cell receptor 346 (TCR)-transgenic mouse line in which 90% of CD8⁺ T-cells are specific for MCMV 347 M38 peptide, and measured the percentage of IFN- γ^+ CD8⁺ T cells 6 h later (Figure 7B, 348 schematic model) (Maxi mice; Torti et al., 2011). Remarkably, as illustrated in Figure 349 350 7B, both MCMVm138AIg2 and MCMVm138AIg2/Ig3-infected BMDCs stimulated significantly stronger IFN- γ responses by CD8⁺ T cells as compared to the MCMVwt infected cells. Moreover, the magnitude of the IFN- γ induction observed with these two MCMV mutants, which downregulated CD80 but preserved cell surface levels of ICOSL intact, almost approached the levels obtained in MCMV Δ m138-infected BDMCs. These findings provide evidence for a substantial contribution of the m138 protein in the evasion of the CD8⁺ T-cell immune response via manipulation of the ICOSL:ICOS axis (Figure 7B).

358

359 m138 impairs ICOS-dependent T-cell responses *in vivo* and limits virus control

We then explored the relevance of ICOSL interference by m138 during the acute 360 MCMV infection. First, we sought to confirm that ICOSL downmodulation by MCMV 361 was taking place in the *in vivo* context. Adult BALB/c mice were intraperitoneally (i.p.) 362 infected with 2x10⁶ PFU of MCMV-GFP, and 48 h later the levels of ICOSL were 363 364 analyzed in peritoneal macrophages by flow cytometry. As shown in Figure 8A, we observed a significant reduction of ICOSL levels, in parallel to those of MHC I used as 365 a positive control, on the surface of the GFP+ MCMV-infected as compared to the 366 367 uninfected GFP- macrophages. In addition, we directly assessed whether ICOSL was being specifically downregulated by m138 on peritoneal DCs during the in vivo 368 infection. Thus, BALB/c mice were mock-infected or i.p. infected with 1x10⁶ PFU of 369 370 MCMVwt or MCMV∆m138, and at 6 hpi cell surface levels of ICOSL and CD80 were 371 determined by flow cytometry on infected peritoneal DCs (positive for the MCMV protein m04) and compared to those on peritoneal DCs derived from mock-infected 372 mice. Figure 8B illustrates a marked MCMVwt-induced downmodulation of ICOSL on 373 374 peritoneal DCs, and a subsequent significant augmentation of the levels of this molecule in the absence of m138, on the surface of MCMVAm138-infected peritoneal DCs. In the 375

376 case of CD80, although the downmodulation caused by MCMVwt was subtle, a clear 377 increase of CD80 levels was detected on MCMV∆m138-infected cells when compared 378 to both mock-infected and MCMVwt-infected DCs. Therefore, these results confirmed a role of m138 downmodulating ICOSL and CD80 on primary mouse DCs (Figure 8B). 379 380 It has been previously described that the MCMV mutant depleted of m138 is attenuated 381 early after infection in an NK-dependent manner, attributing this phenotype to the 382 already reported activities of this viral protein downregulating NKG2D ligands (Lenac et al., 2006). Taking in consideration m138 effects on the two co-stimulatory molecules 383 384 CD80 and ICOSL, we sought to assess the contribution of m138 at later times of the acute infection by comparing the *in vivo* phenotype of MCMVm138AIg2 with that of 385 MCMVAm138 and MCMVwt under conditions that included depletion of NK cells or 386 combined depletion of NK cells and CD4⁺ and CD8⁺ T cells. Of note, previous work 387 with MCMVm138AIg2 showed that this mutant virus was capable to downregulate 388 389 NKG2D ligands MULT-1 and RAE-1ɛ, but not H60 cell surface molecules (Arapović et al., 2009; Lenac et al., 2006). The information of the effects that MCMVwt and mutants 390 391 have on these m138 targeted host molecules on the surface of infected cells is indicated in part C of Figure 8. C57BL/6 mice were intravenously (i.v.) infected with $2x10^5$ PFU 392 393 of the different viruses, left untreated or treated with the antibodies to deplete specific lymphocyte subsets, and viral titers in salivary glands and lungs were quantified 14 days 394 395 post infection (dpi) (Figure 8D, schematic representation of the assay). As illustrated in Figure 8D, in the salivary glands, viral titers of MCMVm138AIg2, a mutant which is 396 397 unable to downregulate H60 and ICOSL, were lower than those of MCMVwt. In fact, the MCMVm138AIg2 titers in this organ were below the detection limits for all 398 399 animals, in a similar way as in MCMVAm138 infected mice. NK cell depletion led to a 400 substantial increase of both MCMVAm138 and MCMVm138AIg2 infection in this 401 organ, but importantly, MCMVm138AIg2, which was downmodulating CD80 but not ICOSL, was still heavily attenuated as compared to MCMVwt under these conditions. 402 403 This finding indicated that ICOSL targeting by m138 is important for the virus to 404 increase its load in salivary glands. Conversely, the downregulation of CD80 by m138 405 did not seem to play a major role during MCMV replication in this organ. Furthermore, when besides NK cells, $CD4^+$ and $CD8^+$ T cells were depleted, MCMVm138 Δ Ig2 406 growth in the salivary glands was completely restored, indicating that m138 via 407 408 interference with ICOSL evades T-cell responses. It is important to note that when NK cells together with CD4⁺ and CD8⁺ T cells were depleted, MCMV Δ m138 seemed to be 409 410 slightly attenuated. This may suggest that m138 is capable to perform additional 411 immune evasion activities independent of NK and T cells. Similar results were obtained 412 when viral titers were evaluated in the lungs of the infected animals, although in this 413 case the contribution of m138 via ICOSL in the control of the MCMV infection seemed 414 to be less significant (Figure 8D).

MCMV has been reported to induce the accumulation of virus-specific IL10⁺ CD4⁺ T 415 416 cells in an ICOSL-dependent manner in salivary glands (Clement et al., 2016). Thus, we directly addressed the impact of m138 on the evasion of MCMV-specific CD4⁺ T cells 417 418 responses in various organs. To this end, we adoptively transferred TCR-transgenic CD4⁺ T cells specific for the M25 protein (M25-II; Mandaric et al., 2012) into C57BL/6 419 SCID mice, depleted them of NK cells, and one day later infected them with $2x10^5$ PFU 420 of MCMVwt or MCMVAm138 (See schematic model in Figure 8-figure supplement 1). 421 Seven days after infection, the expansion of CD4⁺ T cells was determined in the spleen, 422 lungs and salivary glands. The data, illustrated in Figure 8-figure supplement 1, show 423 that the frequencies of CD4⁺ T cells increased in the three organs analyzed upon 424 MCMV infection. Moreover, a role of the viral m138 protein participating in immune 425

426 evasion of $CD4^+$ T cells could be observed in spleen and lungs when comparing data 427 from MCMVwt and MCMV Δ m138 infections, although this was not the case in the 428 salivary glands.

429

The ICOSL:ICOS axis contributes to the generation of MCMV-specific humoral immune responses *in vivo*

432 We also sought to determine the importance of ICOSL-mediated co-stimulation for mounting MCMV-specific T-dependent antibody responses. We approached this, by 433 inhibiting ICOSL:ICOS interaction during the acute MCMV∆m138 infection via the 434 435 administration of a blocking anti-ICOSL antibody. Groups of BALB/c mice were infected with $2x10^6$ PFU of MCMV Δ m138 and treated with or without an anti-ICOSL 436 mAb, starting one day prior infection. Salivary gland draining lymph nodes and spleens 437 were extracted in order to analyze by flow cytometry different T and B lymphocyte 438 439 subsets, and blood collected, at day 14 post infection. As illustrated in Figure 9A, a marked decrease of the percentage of Tfh cells in both spleen and lymph nodes was 440 441 observed when infected mice were deprived of ICOSL-mediated signals. In addition, 442 while the percentage of follicular B cells was not substantially altered, or was even 443 slightly higher, upon ICOSL blockade, GC B cells in lymph nodes were dramatically 444 reduced. Consistent with these observations, an analysis by immunofluorescence of 445 splenic sections revealed that GCs were smaller in size in the infected mice that received anti-ICOSL antibody as compared to mice that did not received it, whereas this 446 447 was not the case of the follicles, whose sizes seemed not to be affected by the treatment (Figure 9B). These results, which are in agreement with the phenotype associated with 448 449 ICOS absence, pointed to a disturbed production of MCMV specific antibodies during 450 the primary infection under conditions of ICOSL blockade. No significant differences in the percentage of other cell subsets such as marginal zone B cells, B1 B cell subsets, plasma cells, or overall $CD4^+$ and $CD8^+$ T cells between the two groups of infected animals were detected (Figure 9-figure supplement 1). In addition, the blockade of ICOSL also resulted in an increased percentage of naïve $CD4^+$ T cells in the spleen and decreased percentages of memory $CD4^+$ T cells in spleens and lymph nodes (Figure 9A), an indication that long lasting immune protection to MCMV could be also impaired in the absence of ICOSL:ICOS signaling.

Due to the above results and the implication of ICOS in promoting T-dependent 458 antibody responses, we assessed by ELISA whether the levels of MCMV-specific 459 460 antibodies in the sera of the infected mice were altered after ICOSL blockade. We observed that mice that received the anti-ICOSL antibody had significantly reduced 461 462 levels of total IgG specific for MCMV than those that did not receive it (Figure 10A). 463 When we evaluated the serum levels of the predominant subclasses of natural antibodies, a substantial decreased production of MCMV-specific IgG1 and IgG2a and 464 465 b was detected in infected animals in which ICOSL was blocked, while no differences were found in the production of MCMV-specific IgG3 or IgM responses between both 466 groups (Figure 10A). These results indicated that ICOSL-mediated co-stimulation was 467 468 crucial for the development of MCMV-specific IgG1 and IgG2 responses.

The observed alterations in the humoral responses prompted us to conduct *in vitro* neutralization assays of MCMV with the serum of the infected mice. As illustrated in Figure 10B, sera from mice that received the anti-ICOSL antibody exhibited a significant lower capacity to neutralize MCMV compared to those that did not received it. Similar findings were obtained when the neutralization assays were performed in the presence of complement (Figure 10-figure supplement 1). In conclusion, our findings indicate a prominent role of ICOSL:ICOS interactions in the induction of effective Tand B cell responses during MCMV infection.

477

478 HCMV reduces cell surface levels of ICOSL on APCs

We then investigated if HCMV has also the capacity to interfere with cell surface 479 expression of ICOSL in APCs. To this end, human primary monocyte-derived 480 481 macrophages were infected with HCMV-GFP (TB40/E strain), and analyzed by flow cytometry 72 hours after infection. In addition, we tested the viral effects on the THP-1 482 cell line differentiated by treatment with the protein kinase-C agonist phorbol-12-483 484 myristate-13-acetate (PMA). As shown in Figure 11A, in both cell types, HCMV 485 infection resulted in a marked reduction in cell surface ICOSL expression compared to 486 non-infected cells in the same culture or to mock-infected cells. In contrast, cell surface 487 expression of CD70 remained unaffected, indicating that ICOSL molecules were specifically targeted in HCMV infected cells. Kinetic assays performed in THP-1 cells 488 489 indicated that by 24 hpi ICOSL levels were already drastically reduced (Figure 11B). 490 As shown in Figure 11C, the fact that upon infection with UV-inactivated HCMV ICOSL density at the plasma membrane was not significantly different from that of 491 492 mock-infected control cells, suggested that the expression of one or more viral gene products were required to downmodulate ICOSL. We also analyzed whether the total 493 494 levels of ICOSL were altered upon infection, by carrying out immunoblot analysis on uninfected or HCMV infected protein lysates using an anti-ICOSL polyclonal antibody. 495 As can be seen in Figure 11D, ICOSL in the THP-1 uninfected cells migrated as a broad 496 band of approximately 70 kDa. In contrast, after infection with HCMV, the levels of 497 ICOSL were drastically reduced. Interestingly, we observed that treatment with 498 leupeptin and bafilomycin was not able to significantly restore ICOSL expression. 499

500

501 Additional herpesviruses also target cell surface ICOSL

Finally, we asked whether, similar to murine and human CMVs, other human 502 503 herpesviruses are also able to alter ICOSL cell-surface expression during the course of the infection. We focused on HSV-1 and HSV-2, and infected THP-1 cells using GFP 504 versions of these viruses. Notably, as illustrated in Figure 11E, the levels of ICOSL 505 506 were reduced during infection of both HSV-1-GFP and HSV-2-GFP compared to those of or mock-infected cells. In contrast, surface expression of CD70 did not change, 507 508 confirming the specificity of the findings. Moreover, the observation that upon infection of THP-1 cells with UV-inactivated HSV-1 and HSV-2, only a partial downregulation 509 of ICOSL was observed, indicated that these two human viruses also harbor genes 510 511 targeting ICOSL (Figure 11E). Last, when we evaluated by western blot ICOSL 512 expression in whole THP-1 cell lysates, a clear reduction of the levels of this molecule could be appreciated upon infection with both HSV-1 and HSV-2 (Figure 11F). 513 514 Altogether, these findings demonstrate that ICOSL downregulation is a strategy used by different herpesviruses. 515

516 **Discussion**

517

518 Co-stimulatory molecules play a decisive role in shaping the extent and nature of the cell-mediated adaptive immune response by tuning T-cell activation. Therefore, it is not 519 surprising that pathogens, including viruses, have devised mechanisms to abrogate their 520 521 signaling and blunt host responses that would otherwise limit their replication (Khan et al., 2012). In this study, we demonstrate that the ligand for the co-stimulatory molecule 522 523 ICOS is dramatically diminished from the surface of APCs during infection by different herpesviruses. With a primary focus on MCMV, the most widely used model to study 524 CMV infection, we show that the downregulation of ICOSL restricts the magnitude of 525 MCMV-specific T-cell responses and potentiates viral burden in vivo. 526

We describe here that ICOSL expression is slightly induced upon cell exposure to 527 MCMV, presumably due to viral sensing by pattern recognition receptors. However, 528 MCMV rapidly removes this molecule from the surface of infected cells by expressing 529 m138. Infections with an MCMV lacking the m138 gene, and assays with the viral gene 530 expressed in isolation, indicate that m138 is necessary and sufficient to decrease ICOSL 531 532 cell surface levels. The early-expressed m138 protein, which is an Fc receptor homologue, has been shown not only to bind the constant Fc domain of IgG, but also to 533 534 downmodulate the expression of three cellular ligands of the activating NKG2D receptor, RAE-1ɛ, H60, and MULT-1, and another B7 family molecule, CD80 535 (Arapović et al., 2009; Lenac et al., 2006; Mintern et al., 2006; Thäle et al., 1994). 536 537 Consequently, this viral protein holds the potential to control the antiviral function of NK and T cells, as well as the humoral response. Hence, the m138 early glycoprotein 538 539 provides an excellent example of how CMVs have refined proteins to execute multiple 540 immune-evasion functions. It is becoming increasingly clear that the evolution of

multifunctional proteins is not only a hallmark of RNA viruses, with limited genome 541 542 sizes and relatively small number of genes, but that it is also employed by large DNA viruses to make optimal use of their coding capacity. For instance, MCMV produces the 543 544 multifaceted immunomodulatory protein m152, which is capable of downregulating MHC class I molecules and different RAE-1 isoforms, as well as modulating the cGAS-545 STING pathway, thereby evading type I IFN-, NK- and T cell-dependent immune 546 responses to MCMV infection (Fink et al., 2013; Krmpotić et al., 1999; Lodoen et al., 547 2003; Stempel et al., 2019; Ziegler et al., 1997). Moreover, we have recently 548 demonstrated that by interfering with AP-1 mediated protein sorting, the m154 549 550 glycoprotein targets a broad-spectrum of cell surface molecules implicated in the 551 antiviral NK and T-cell responses (Strazic et al., 2020; Zarama et al., 2014). In HCMV, 552 this concept is best exemplified by the US12 family, whose members, as it will be 553 discussed below, have been reported to alter the expression of numerous plasma membrane proteins, mainly NK ligands, adhesion proteins and cytokine receptors 554 555 (Fielding et al., 2017).

556

m138 is a 69 kDa type I transmembrane glycoprotein, largely localized in the ER and 557 558 lysosomal compartments, and shown to be further processed into a 105 kDa highly glycosylated form (Mintern et al., 2006). Based on the ability of MCMV infected cells 559 to bind IgG, m138 was reported to be a cell surface resident protein, a feature shared by 560 the different viral Fcy receptors (Corrales-Aguilar et al., 2014; Lenac et al., 2006). 561 Consistent with its location at the plasma membrane, the viral protein was shown to 562 perturb the endocytosis of surface RAE-1ɛ and MULT-1, interfering with the clathrin 563 564 dependent endocytosis of this later cellular target, altering its recycling and leading to its subsequent degradation in lysosomes (Arapović et al., 2009; Lenac et al., 2006). A 565

different mode of action was reported for m138 in the downregulation of CD80, 566 567 targeting the cellular molecule when newly synthesized early in the secretory pathway and mislocalizing it to lysosomal compartments (Mintern et al., 2006). To date, studies 568 569 on the maturation and posttranslational modifications of ICOSL are still lacking, but our observations are compatible with the notion that, as in the case of CD80, m138 interacts 570 571 with ICOSL, preventing it to mature and reach the plasma membrane, and driving this 572 molecule to lysosomal degradation. Accordingly, we found that during MCMV infection, m138 and ICOSL colocalize in intracellular compartments, where the viral 573 protein is primarily expressed, and that upon treatment with lysosomal inhibitors the 574 575 levels of both ICOSL and m138 augment. Moreover, our co-precipitation experiments 576 demonstrate that indeed m138 directly associates with ICOSL. The details on how the 577 interactions of m138 with its structurally diverse targets can potentially occur remain to 578 be elucidated. In this regard, solving the crystal structure of m138 alone or bound to its cellular targets may be of great value for understanding its versatility and different 579 580 modes of action.

581

Due to the multiple cellular targets of m138, dissecting the functional consequences of 582 583 lessening ICOSL cell surface levels on virally infected cells appeared to be complicated. m138 was predicted to contain an ectodomain with three putative Ig-like domains, 584 exhibiting a relatively low but yet significant sequence homology with the Ig-like 585 domains of murine FcyRs CD16 and CD32 (Budt et al., 2004; Lenac et al., 2006). 586 Previous work indicated distinct m138 structural requirements to downmodulate the 587 588 different NKG2D ligands (Arapović et al., 2009; Lenac et al., 2006; Mintern et al., 2006). Thus, by generating versions of the m138 protein devoid of some of its Ig 589 domains, and through the use of MCMV recombinants bearing similar deletions within 590

591 the viral protein, we determined that the downregulation of the two B7-molecules, 592 ICOSL and CD80, was dependent on the N-terminal m138 Ig domain. However, while the middle and membrane-proximal Ig domains of m138 were largely dispensable for 593 594 disturbing CD80, they needed to be preserved for ICOSL cell surface removal. This result indicates a distinct mode of action of m138 to target the two costimulatory 595 596 molecules, and gave us the opportunity to separate the corresponding impacts on T-cell 597 activation. Optimal T-cell activation is characterized by rapid proliferation, cytokine production and efficient effector functions. Importantly, employing an *in vitro* antigen 598 presentation assay and the m138 mutant MCMVs, we showed that via ICOSL 599 downmodulation, m138 contributes to impair antiviral CD8⁺ T-cell responses. This 600 agrees with the earlier evidence that the m138 protein expressed in isolation is capable 601 602 to reduce the ability of DCs to promote T-cell activation in a CD80-dependent manner, 603 and the fact that applying a blocking anti-CD80 antibody only partially reverted these 604 effects (Mintern et al., 2006). Our observations, however, in the context of the infection, 605 point to a prominent role of the ICOSL-dependent m138 function compromising T-cell 606 stimulation. The m138 protein has not an ortholog in HCMV. However, we demonstrate that following a productive HCMV infection of primary monocyte-derived 607 608 macrophages or differentiated THP-1 cells, which express high levels of ICOSL, a strong ICOSL cell surface downregulation also takes place, and that this process 609 requires viral gene expression. Using a multiplexed proteomic approach and HCMVs 610 611 with deletions of each individual ORF of the US12 viral family, Fielding and co-612 workers had previously described that members of this family selectively target a number of plasma membrane proteins crucial for NK cell activity, adhesion, and 613 cytokine signaling during HCMV infection of human fibroblasts (Fielding et al., 2017). 614 Interestingly, in these assays, and despite the low levels of ICOSL in human fibroblasts, 615

616 no reduction of cell surface ICOSL could be observed after infection with HCMVs 617 deleted in either US16 or US20, strongly suggesting that these two HCMV products are involved in ICOSL downregulation. Our findings also indicate that HCMV not only 618 619 leads to diminished cell surface ICOSL, but also to an abrogation of its expression in whole cell levels, via a lysosomal degradation-independent process. Importantly, a 620 621 similar complete loss of ICOSL on differentiated THP-1 cells was observed during infection by two α -herpesviruses, HSV-1 and HSV-2. In this case, though, both the 622 623 mechanism as well as the identity of the viral proteins involved in this process remain to 624 be defined.

625

The importance of the ICOSL: ICOS pathway has been explored in several models of 626 627 bacterial and parasitic infections (Wikenheiser and Stumhofer, 2016). However, to date, only a limited number of studies on murine models of infection with RNA viruses 628 629 (LCMV, VSV, and influenza virus), in conditions of ICOS deficiency or blockade with an ICOSL-Ig molecule, have been reported, and shown that ICOS triggering plays a 630 631 marginal although significant role in the development of CD4⁺T-cell effector responses 632 (Bertram et al., 2002; Kopf et al., 2000). But, persisting DNA viruses, with infections more dependent on cell-mediated immune control, may differ. Besides the role played 633 by ICOS in directing effector T-cell activation, proliferation and differentiation, this 634 635 molecule has been crucially implicated in the generation of T-dependent antibody responses. Thus, in this study we examined whether anti-MCMV humoral immune 636 637 responses were altered in the absence of ICOS signaling. Overall, our data employing a blocking monoclonal anti-ICOSL antibody in the context of the acute MCMV infection 638 revealed a high importance of the ICOSL:ICOS axis in the formation of Tfh cells and 639 subsequent GC B-cell development in spleens and lymph nodes follicles, consistent 640

with what has been previously observed in other in vivo experimental models of 641 642 infection (Wikenheiser and Stumhofer, 2016). Importantly, as a consequence of the observed effects, ICOSL blockade was associated with a lower production of MCMV-643 644 specific IgG1 and IgG2 antibodies. Furthermore, a decreased capacity of the antibodies MCMV was 645 generated to neutralize also observed. Notably, while the 646 CD80/CD86:CD28 co-stimulatory pathway has been shown to be also involved in the 647 induction of Tfh cells and class switching of MCMV-specific antibodies, we find that this pathway is not capable to compensate the defects observed in the absence of ICOS 648 signaling, evidencing the non-redundant role of the two axis in this scenario (Welten et 649 650 al., 2016). We have not directly addressed here whether the lack of ICOSL co-651 stimulation is associated with a deficient viral control, due to the highly attenuated 652 phenotype of the MCMV defective in m138 employed in the study. Remarkably, a 653 reduction of splenic CD4⁺ memory T cells was also observed in our assays upon ICOSL blockade, further supporting the potential significance of the ICOSL: ICOS axis in the 654 655 long term protection against MCMV. Of interest, ICOS- and ICOSL-deficient patients have been associated with combined T- and B-cell immunodeficiency, and importantly, 656 with an increased susceptibility to viral infections (Roussel et al., 2019; Schepp et al., 657 2017). Moreover, while the infectious phenotype of these patients varied, a high 658 incidence of recurrent herpesvirus infections, mostly including herpes simplex and 659 cytomegalovirus infections, was observed. 660

661

It was previously shown that deletion of m138 or both m138 and the CD86 downmodulator m147.5 from MCMV has a dramatic impact on viral load during acute infection (Arens et al., 2011; Crnković-Mertens et al., 1998). To directly address the potential importance of m138-mediated downregulation of ICOSL on viral growth *in*

vivo we employed the recombinant MCMV expressing m138 without the middle Ig 666 667 domain, and therefore able to downmodulate CD80 and CD86 but not ICOSL in infected APCs. The fact that under conditions of NK cell depletion the viral mutant was 668 669 still attenuated at late times post infection, particularly in the salivary glands, and the nearly complete reversion of this defective phenotype in the absence of NK cells and T 670 671 cells, indicated that m138 by interfering with ICOSL contributes to subvert T-cell 672 responses in vivo. By performing adoptive transfer assays of exogenous M25-specific transgenic CD4⁺ T cells into C57BL/6 SCID mice, which were depleted of NK cells, 673 and infected with MCMVwt or the MCMV lacking m138, we evaluated the impact that 674 the viral protein may have on immune evasion of CD4⁺ T cells in various organs. We 675 observed that m138 clearly contributes to diminish M25-specific CD4⁺ T cell 676 677 proliferation in spleen and lungs of infected mice, but not in salivary glands, where 678 virus specific CD4⁺ T cells are important for control of the viral infection. It must be noted, however, that since in the study we only measured M25-specific responses, we 679 680 cannot discard that in the salivary glands m138 may be influencing in a different way 681 CD4⁺ T cell responses specific for other MCMV epitopes. Altogether, our results support the notion that downmodulation of ICOSL by m138 represents an effective 682 683 immune evasion strategy during the acute MCMV infection. Taking in account these observations, an aspect that deserves to be explored is whether these ICOSL-related 684 activities can be employed by additional herpesviruses or other viral pathogens as a 685 mean to escape host immune surveillance. 686

687

In conclusion, in this study we present a novel viral tactic to impair T-cell activation, based on the interference with the ICOS:ICOSL co-stimulation pathway. To this end, the herpesviruses analyzed so far seem to exploit "self" proteins, evolved during coevolution with their hosts, being in the case of murine CMV, a multitasking
immunoevasin. Ultimately, the study of these immunoevasin should provide not only
new insights into viral pathogenesis, but also enlighten us about critical biological and
immunological processes that promote viral control.

695 Material and methods

696

697 **Ethics statement**

698 All procedures involving animals and their care were approved (protocol number CEEA 308/12) by the Ethics Committee of the University of Barcelona (Spain) and the Animal 699 700 Welfare Committee at the University of Rijeka (Croatia) and were conducted in 701 compliance with institutional guidelines as well as with national (Generalitat de 702 Catalunya decree 214/1997, DOGC 2450) and international (Guide for the Care and Use 703 of Laboratory Animals, National Institutes of Health, 85-23, 1985) laws and policies. 704 Human blood was obtained from healthy volunteer donors through the Blood and 705 Tissue Bank of the Catalan Department of Health (Barcelona, Spain). Utilization of 706 blood products for the experiments conducted was approved by the Ethics Committee of 707 the Hospital Clinic of Barcelona (Barcelona, Spain), and according to the principles of the Declaration of Helsinki. 708

709

710 Cell cultures

711 NIH3T3 (mouse embryonic fibroblasts), SVEC4-10 (SV40-transformed mouse 712 endothelial cells), HFF (human foreskin fibroblasts), HEL299 (human embryonic lung 713 fibroblasts), MEFs (primary mouse embryonic fibroblasts), MEFs immortalized with 714 p53 (kindly provided by Dr. Jay Nelson [Oregon Health Sciences University, Portland, USA]), and Vero cells were cultivated in Dulbecco's modified Eagle's medium 715 716 (DMEM) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 50 U/mL of 717 penicillin, 50 g/mL of streptomycin, and 10% fetal bovine serum (FBS). IC-21 (mouse 718 peritoneal macrophages transformed with SV-40), DC2.4 (mouse dendritic), NS1 (mouse myeloma), THP-1 (human monocytic) and 300.19 (mouse pre-B) cells were 719

720 cultured in RPMI-1640 medium, supplemented as indicated above, and for THP-1 and 721 300.19 cells, 0.05 mM 2-mercaptoethanol was added. Primary mouse peritoneal macrophages were elicited from peritoneal exudate cells from BALB/c mice receiving 1 722 723 mL of thioglycolate i.p. 4 days before the extraction. Primary peritoneal dendritic cells were isolated according to Ray and Dittel (2010). Splenocytes and lymph nodes 724 725 obtained from mice were subjected to a manual disaggregation and treatment with red 726 blood cell lysis buffer (0.15 M NH4Cl, 0.01 M Tris HCL) to obtain cell suspensions. 727 Primary mouse dendritic cells and macrophages from bone marrow of femur bones from BALB/c mice or C57BL/6 were obtained after 7 days of culture in RPMI-1640 728 729 medium supplemented as indicated above, with the addition of granulocyte-macrophage colony-stimulating factor (GM-CSF) at days 3 and 6 from extraction. Attached cells 730 731 were enriched in macrophages whereas suspension fractions were enriched in dendritic 732 cells. Both type of cells were plated in flat-bottom 24-well dishes with the supplemented RPMI-1640 medium at a concentration of $2x10^5$ cells/well. Dendritic and 733 734 macrophage differentiation were confirmed by flow cytometry using the markers 735 CD11c and, F4/80, respectively. Primary human monocytes were obtained from PBMCs isolated by Ficoll-Paque density-gradient centrifugation from fresh blood 736 samples of human healthy donors. Monocyte-derived macrophages (MDM) were 737 differentiated after culturing monocytes for 5 days in RPMI-1640 medium 738 739 supplemented as indicated for mouse primary cells, with 50 ng/mL of GM-CSF. Cell lines were routinely tested for mycoplasma contamination with MycoAlert Mycoplasma 740 741 Detection Kit from Lonza.

742

743 Viruses and infections

The bacterial artificial chromosome (BAC)-derived MCMV strain MW97.01, here 744 745 referred as MCMVwt (Wagner et al., 1999), and the MCMV-GFP recombinant virus, a derivative of MW97.01 carrying the GFP gene (Mathys et al., 2003), were used as 746 747 parental viruses throughout the study. Recombinant strains MCMV-GFPA15 lacking genes from m128 to m138 (termed here MCMV-GFPAm128-m138) and MCMVAm138 748 749 lacking the m138 gene, have been described previously (Lenac et al., 2006), as well as 750 recombinant strain MCMV-GFP $\Delta 1$ lacking genes from m1 to m17 (termed here MCMV-GFP∆m1-m17; Brune et al., 2006). MCMV mutants containing m138 versions 751 without Ig2 domain (MCMVm138AIg2), or without Ig2 and Ig3 domains 752 753 (MCMVm138AIg2/Ig3) were also described in Lenac et al., 2006. Viral stocks were 754 grown by infecting MEFs cells at a low moi using DMEM supplemented as stated 755 above, except that 3% FBS was used. Cell supernatants were recovered when maximum 756 cytopathic effect was reached, and cleared of cellular debris by centrifugation at 1750 g for 10 min. The HCMV strain TB40/E carrying the GFP gene was used in the study 757 (termed here HCMV-GFP; Sinzger et al., 2008). HCMV stocks were prepared as 758 759 indicated for MCMVs, but using in this case HEL299 or HFF cells. HSV-1 and HSV-2 containing the GFP gene were kindly provided by Dr. Antonio Alcamí (Autonomous 760 761 University of Madrid, Spain). Both viruses were grown in Vero cells. Viral titers were 762 determined by standard plaque assay on primary BALB/c MEFs, MEFs p53, HEL299 or Vero cells for MCMV, HCMV, or HSV-1 and HSV-2, respectively. Infections of 763 764 murine peritoneal macrophages, bone marrow dendritic cells and IC-21 cells included a 765 centrifugal enhancement of infectivity step (Hudson, 1988). C57BL/6 derived DCs were infected by incubating cells in suspension with the virus for 30 min in a small volume 766 767 $(c=10^7 \text{ cells/mL})$ with occasional agitation at 37°C. THP-1 cells were activated for 24 h with 50 ng/mL PMA (Sigma-Aldrich) prior the infection. THP-1 cells and MDM were 768

769	infected in the presence of PMA or GM-CSF, respectively, for 16 hours, and also
770	included a step of centrifugal enhancement of infectivity. UV-inactivation of virus was
771	performed using a UV crosslinker (HL 2000 hybrilinker) for 3 min at 360 mJ/cm ² .

772

773 Antibodies

For flow cytometry analysis we used the following anti-mouse antibodies: ICOSL-774 775 biotin or ICOSL-PE (clone HK5.3), MHCI-PE (clone M1/42), B7.1-APC (clone 16-776 10A1), CD84-PE (clone mCD84.7), CD11c-A647 or -APC (clone N418), F4/80-PE (clone BM8), B220-PB (clone RAE-6B2), CD5-PE (clone 53-7.3), CD138-PECy7 777 778 (clone 281-2), CD3-A488 (clone 17A2), CD4-PB (clone GK1.5), CXCR5-APC (clone L138D7), and CD19-A647 (clone 6D5), purchased from Biolegend; CD23-PE (clone 779 780 B3B4), CD95-A647 (clone Jo2), CD44-FITC (clone IM7), and CD8-PE (clone 53-6.7), obtained from BD Biosciences; CD62L-APC (clone MEL-14), CD44-APC or -781 AlexaFluor700 (clone IM7), CD21-PECy7 (clone 8D9), GL7-A488 (clone GL7), CD3-782 783 PerCP-Cy5.5 or -PE-eFluor610 (clone 145-2C11), ICOSL-PE (clone HK5.3), B7.1-784 APC (clone 16-10A1), CD3-PE-eFluor610 (clone 17A2), CD8-APC, -SuperBright780 or -FITC (clone 53-6.7), CD4-FITC (clone GK1.5), CD45.1-SuperBright600 (clone 785 786 A20), CD45.2-eFluor506 (clone 104), CD19-PE-eFluor610 (clone eBio1D3), NKp46-PE-eFluor610 (clone 29A1.4), CD11b-PE-Cy7 (clone M1/70), CD11c-PerCP-Cy5.5 787 (clone N418), MHC II-eFluor450 or -APC-eFluor780 (clone M5/114.15.2), TCR V 788 alpha 11-APC (clone RR8-1 and IFN-y (clone XMG1.2), from eBioscience, Thermo 789 790 Fisher Scientific; PD-1-PE (clone J43.1) and CD3-PECy7 (clone 145-2C11), from 791 Tonbo; and IgM-FITC (polyclonal), from Southern Biotech. Armenian hamster IgG (clone eBio299 Arm) and rat IgG2a kappa (clone eBR2a) isotype controls were 792 purchased from Thermo Fisher Scientific. The rat anti-mouse ICOSL (clone HK5.3), 793

anti-mouse NK1.1 (clone PK136), anti-mouse CD8 (clone YTS 169.4), and anti-mouse 794 795 CD4 (clone GK1.5) used for the in vivo assays were obtained from Bioxcell. The antimouse ICOSL (clone 599841) used for immunochemistry was purchased from 796 797 Novusbio Biologicals. Biotin anti-human ICOSL (clone MIH12), CD4-APC (clone RPA-T4), and CD70 (clone 2F2) were purchased from ThermoFisher, BD Biosciences, 798 799 and Immunotools, respectively. Anti-human ICOSL (polyclonal), anti-actin (clone C4), 800 anti-HA (clone C2974), anti-GFP (polyclonal), and anti-human IE1 (clone 8B1.2), used 801 for Western blots, were from Elabscience, MP Biomedicals, Cell Signaling MP, Abcam, and Merck Millipore, respectively. The anti-mouse IE1 (named Croma101) and the anti-802 803 human Fc IgG (clone 29.5; Fc specific) were previously described (Trgovcich et al., 2000; Pérez-Carmona N et al., 2015). Anti-mouse m04 (clones m04.17 or m04.16) 804 805 antibody used as a marker of MCMV infection was produced in the Center for 806 Proteomics (Faculty of Medicine, University of Rijeka, Croatia), and was described previously (Železnjak et al., 2019). The anti-mouse IgG-A555 was purchased from Life 807 808 Technologies, the anti-rat IgG-A488 and anti-mouse IgG-PE or -A647 from Jackson ImmunoResearch, the anti-mouse IgG1-PerCP-eFluor710 and anti-mouse IgG2b-FITC 809 from eBioscience, Thermo Fisher Scientific, the anti-rabbit IgG-HRP from Promega 810 and the anti-mouse IgG-HRP from Sigma-Aldrich. The streptavidin-PE, -A555, or -811 HRP conjugates were purchased from BD Biosciences, ThermoFisher, and Roche, 812 respectively. The anti-m138 mAb (clone m138.1.120) was generated by fusing an NS1 813 myeloma cell line with spleen cells from a BALB/c mouse immunized three times with 814 300.19 cells expressing at the cell surface HA-m138. The m138.1.120 mAb was 815 subcloned and purified using an Affi-Gel protein A MAPS II kit (Bio-Rad) as indicated 816 before (Engel et al., 2011). Fixable viability dye eFluor780 and eFluor506 (1000x, 817 eBioscience, Thermo Fisher Scientific) were used to stain dead cells. 818

820 Plasmid constructions

821 HA-m138, containing the N-terminal HA-tagged m138 molecule without its signal 822 peptide, was constructed by PCR using as a template DNA extracted from MCMV virions and primers m138PstIFor and m138PstIRev. The resulting PCR product was 823 inserted into the pGEM-T vector, and subsequently, the m138 fragment was excised 824 825 with BglII and inserted in frame with the HA tag at the N-terminal end into the mammalian expression vector pDisplay (Invitrogen) opened with PstI. The m138-GFP 826 plasmid was obtained by PCR employing primers m138BamFor and m138BamRev, 827 828 containing a BamHI restriction site, and DNA from MCMV virions as a template. The PCR product was inserted into the pGEM-T vector, and then the m138 fragment 829 830 without its terminal codon was excised with *Bam*HI and inserted in frame with the GFP 831 at the C-terminal end into the pEGFP-N3 plasmid (clontech) opened with BamHI. m138\DeltaIg1-GFP, without the first Ig domain of m138 (322nt-681nt), m138\DeltaIg2-GFP, 832 833 without the second Ig domain of m138 (697nt-1029nt), and m138\Dig2/3-GFP, without the second and third Ig domains of m138 (697nt-1416nt), were constructed as follows: 834 first, independent PCR products were generated using as a template the pEGFP-N3 835 836 m138-GFP vector, two common external primers (m138BamFor and m138BamRev), and for each construct, two internal complementary primers bearing the corresponding 837 deletions: SOEm138∆Ig1Rev SOEm138∆Ig1For 838 and for m138 Δ Ig1; 839 SOEm138\Delta Ig2Rev and SOEm138\Delta Ig2For for m138\Delta Ig2; and SOEm138\Delta Ig2/3Rev and SOEm138 Δ Ig2/3For for m138 Δ Ig2/3. Splicing by overhang extension (SOE)-PCR was 840 841 then performed to join the two PCR fragments obtained for each m138 mutant using the external primers. These new PCR products were inserted into the pGEM-T vector, and 842 then fragments of the m138 mutants without their terminal codon stop were excised and 843

cloned in frame with the GFP at the C-terminal end into the pEGFP-N3 plasmid opened 844 845 with BamHI. Mouse ICOSL, without its signal peptide, fused to the HA epitope at the N-terminus (HA-ICOSL) was obtained by PCR employing as a template pCMV6-846 847 mouse ICOSL vector (Origene) and primers ICOSLmurineSallFor and ICOSLmurineNotIRev. The resulting PCR product was inserted into the pGEM-T 848 849 vector and a SalI-NotI fragment corresponding to the murine ICOSL was then excised 850 and inserted into the mammalian expression vector pDisplay opened with the same restriction sites. In all cases, the PCR products inserted in the pGEM-T vector were 851 sequenced to validate the nucleotide sequences, and when required, the correct 852 853 orientations of the cloned inserts were assessed employing different restriction sites.

854

855 Flow cytometry analysis

856 Flow cytometry was performed according to the Guidelines for the use of flow cytometry and cell sorting in immunological studies (Cossarizza et al., 2017). To 857 858 minimize non specific staining, all incubations were carried out in the presence of 20% 859 rabbit serum (Linus) and 1% of fetal bovine serum in PBS. Adherent cells were harvested by incubation with 2 mM EDTA or when indicated by treatment with trypsin 860 at 37°C. For intracellular staining, cells were fixed and permeabilized with either the 861 Intracellular fixation & permeabilization buffer set or Foxp3 staining buffer set 862 (eBioscience) following manufacturer's instructions, before antibody incubations. Prior 863 864 to cytometry analysis cell suspensions from spleens, lungs, salivary glands and salivary gland draining lymph nodes were washed and filtered through a 70 µm cell strainer 865 (Biologixs). All samples were acquired with LSRII Fortessa, FACSAria III or 866 FACSCanto II flow cytometers (BD Biosciences) and analyzed with FlowJo Xv10.0.7 867

868 (Tree Star, Inc) software. At least two independent experiments were carried out for869 each subject of analysis.

870

871 Transient and stable transfections

NIH3T3 cells were transiently transfected with 2 µg of the corresponding plasmid using
the Amaxa Cell Line Nucleofactor Kit R according to the manufacturer's protocol.
Likewise, 300.19 and IC-21 cells were transfected employing the Amaxa Cell Line
Nucleofector Kit V. To generate stable 300.19 cell lines expressing HA-m138 or
NIH3T3 expressing HA-ICOSL, transfections were followed by G418 (Invitrogen)
selection.

878

879 Western blot analysis

880 NIH3T3 and THP-1 cells were harvested by scrapping and extracts prepared in lysis buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 150 mM NaCl and 1% Triton X-100) 881 882 supplemented with protease inhibitors (1 mM Na3VO4, 1 mM PMSF, 0.6 µg/mL Aprotinine, 2 µg/mL Leupeptin and 312 µg/mL Benzamidin). When specified, cells 883 were previously incubated with 250 µM leupeptin and 20 nM bafilomycin A1 (Sigma). 884 Lysates were quantified by a bicinchoninic acid (BCA) protein assay kit 885 (ThermoScientific), and 15 µg of proteins were subjected to SDS-PAGE in 10% 886 acrylamide gels and subsequently transferred to nitrocellulose membranes (Protran). 887 The membranes were incubated with the indicated antibodies and blots were developed 888 using the SuperSignal West Pico chemiluminescent substrate (Pierce) according to the 889 manufacturer's protocol. Anti-actin mAb was used as a loading control, and anti-IE1 890 mAbs were used as infection controls. At least two independent experiments were 891 carried out for each subject of analysis. 892

894 **Immunoprecipitation**

NIH3T3 cells non-trasfected or transfected with HA-ICOSL were surface labeled with 895 896 biotin (Sigma-Aldrich) and lysed. Cell lysates were precleared 3 times for 30 min employing protein G-Sepharose (GE Healthcare) and immunoprecipitated by incubation 897 with anti-HA agarose conjugate (Sigma-Aldrich). Samples 898 an from 899 immunoprecipitates were subjected to SDS-PAGE and Western blot analysis. 900 Membranes were incubated with streptavidin-HRP or with anti-HA followed by anti-901 rabbit IgG-HRP. At least two independent experiments were carried out for each subject 902 of analysis.

903

904 **Co-Immunoprecipitation**

905 NIH3T3 cells co-transfected with m138-GFP and HA-ICOSL were lysed with a soft lysis buffer (20 mM Tris HCl pH 8, 100mM NaCl, 2mM EDTA and 0.5% Triton-X-906 907 100) supplemented with Halt protease inhibitor cocktail, during 30 minutes at 4°C. The lysates were incubated with G-Sepharose beads in three rounds for 30 minutes each, 908 followed by an overnight incubation with an anti-HA agarose conjugate. The 909 910 immunoprecipitates were washed four times with Co-IP lysis buffer before the samples were subjected to Western blot analysis. Membranes were incubated with anti-GFP or 911 912 with anti-HA, followed by an anti-rabbit IgG-HRP. At least two independent 913 experiments were carried out for each subject of analysis.

914

915 Immunofluorescence microscopy

NIH3T3 cells and 300.19 cells, either untransfected or stably transfected with HAICOSL or HA-m138, respectively, were cultured on glass coverslips in 24-well tissue

culture plates. When specified, NIH3T3 cells were MCMV infected and exposed to 918 919 lysosomal inhibitors as indicated for the Western blot analysis. At 24 hpi, cells were washed in PBS and fixed and permeabilized using 4% paraformaldehyde and 0.05% 920 921 Triton X-100 (for intracellular staining), or just fixed in paraformaldehyde (for cell surface detection), and subsequently blocked with PBS 6% FBS. Cells were stained 922 923 with anti-m138 mAb or anti-ICOSL, using as secondary antibodies an anti-mouse IgG-A555 or an anti-rat IgG-A488. Nuclei were counterstained with DAPI reagent 924 (Invitrogen). In assays where the LysoTracker Red DND-99 (Molecular Probes) was 925 used, cells were incubated at 37°C for 2 hours with 100 nM of the fluorescence dye, 926 927 fixed with 4% paraformaldehyde, gently permeabilized with 0.02% saponin, and immediately processed as indicated above. In this case, the anti-m138 mAb and an anti-928 929 mouse IgG-A488 were used. The samples were mounted in ProLong Gold antifade 930 reagent (Invitrogen). Cells were examined under a fluorescence microscope at 405 nm (DAPI), at 555-565 nm (A555), and at 495-518 (A488). GFP was observed at 450-490. 931 932 Fluorescence images were obtained using a Nikon Eclipse E600 microscope (Nikon) or an inverted Leica DMI6000B microscope and the LAS AF software from Leica 933 Microsystems (Leica, Wetzlar). A Zeiss LSM880 laser scanning spectral confocal 934 microscope (Zeiss, Jena) equipped with an Axio Observer 7 inverted microscope, blue 935 diode (405nm), Argon (488nm), diode pumped solid state (561nm) and HeNe (633nm) 936 lasers and a Plan Apochromat 63x oil (NA 1.4) immersion objective lenses was also 937 used. DAPI, A-488 and A-555 images were acquired sequentially using 405, 488 and 938 561 laser lines, AOBS (Acoustic Optical Beam Splitter) as beam splitter and emission 939 detection ranges 415- 480, 500-550 nm, and 571-625nm, respectively, and the confocal 940 pinhole set at 1 Airy units. Spectral detection was performed using 2 photomultipliers 941 and one central GaAsP detector. Analysis of the co-localization of m138 and the 942

LysoTracker red fluorescence was determined using the ImageJ software analyzing 20 943 944 cells from each sample. Colocalization was assessed using Coloc2 plugin from FIJI/ImageJ program (Schindelin et al., 2019). A macro of instructions was created to 945 946 process and automate colocalization quantification. Briefly, red and green channel images were background substracted with Rolling Ball Radius of 50 and colocalization 947 was quantified from a region of interest delimiting the cell contour. Manders 948 949 coefficients were analyzed from each image. M2 Manders colocalization coefficient 950 indicates the percentage of m138 colocalizing with lysosomes, and M1 Manders cocoefficient the percentage of lysosomes colocalizing with m138. At least two 951 952 independent experiments were carried out for each subject of analysis.

953

954 Immunohistochemistry

955 Mice were euthanized at the indicated time points and spleens immediately collected within O.C.T. (Sakura) cryo-embedding media at -80°C. Consecutive tissue sections of 956 957 2.5 µm were obtained in the cryostat and fixed/permeabilized in acetone. Unspecific 958 binding was prevented with PBS 6% FBS blocking solution. Antigens were detected with a rat anti-mouse CD45R/B220 and PNA (peanut lectin) biotin (Sigma-Aldrich). 959 After 1 hour of incubation at room temperature, B220 antigen was revealed with anti-rat 960 IgG- A488 and PNA with streptavidin-A555. Labeled tissue sections were visualized 961 with a fluorescence microscope. Four consecutive tissue sections were evaluated from 962 963 three representative mice of each experimental group. Follicle and germinal center areas were calculated from the total spleen sections of one representative mice of each group 964 using ImageJ software. At least two independent experiments were carried out for each 965 966 subject of analysis.

968 Mouse infections, antibody treatment and determination of viral titers

969 Four-week-old BALB/c mice (females and males) were obtained from Harlan (Netherlands) and housed in the vivarium of the Medical School of the University of 970 971 Barcelona under specific-pathogen-free (SPF) conditions. Eight-to-twelve-week-old C57BL/6, TCR transgenic mice specific for M38 (Maxi mice; Torti et al., 2011), TCR 972 transgenic mice specific for M25-II (Mandaric et al., 2012), C57BL/6 SCID and 973 BALB/c mice were housed and bred under SPF conditions at the Central Animal 974 Facility of the Medical Faculty of the University of Rijeka. When specified, ICOSL was 975 blocked by i.p. injection of a rat anti-mouse ICOSL monoclonal antibody (clone HK5.3) 976 977 at a concentration of 100 µg per mouse. The monoclonal antibody was administrated one day before infection and on days 2, 5, 8 and 11 after infection. The efficacy of the 978 979 in vivo ICOSL blockade was assessed by cytofluorometric analyses of spleen cells from 980 treated mice using an anti-ICOSL recognizing the same epitope than the antibody used in the *in vivo* assay. For these assays, mice were i.p. inoculated with 2.5×10^6 981 982 PFU/mouse of tissue culture-propagated MCMVAm138. Mice were observed and 983 weighed during all the experiment and at 14 days post infection, animals were sacrificed, and specific organs were removed, and their sera collected. Salivary gland 984 and lungs were harvested as a 10% (weight/volume) tissue homogenate. Tissue 985 homogenates were sonicated and centrifuged, and viral titers from the supernatants of 986 987 individual mice were determined by standard plaque assays in MEFs, including a centrifugal enhancement of infectivity step. In experiments evaluating the in vivo effect 988 of MCMV infection on ICOSL surface levels, mice were i.p. inoculated with 2x10⁶ 989 PFU/mouse of MCMV-GFP, and 2 days after infection, cells present in the peritoneal 990 991 cavity were harvested with 5 mL of PBS and analyzed by flow cytometry. In depleting assays, eight-to-twelve-week-old C57BL/6 mice were infected i.v. with $2x10^5$ 992

PFU/mouse of MCMVwt, MCMVAm138, or MCMVm138AIg2. On the day of 993 infection and on days 5th and 10th after infection, indicated groups of mice were injected 994 i.p. with 250 µg of anti-mouse NK1.1, 150 µg of anti-CD8, or 150 µg anti-mouse CD4 995 depleting antibodies. At day 14 post infection, mice were sacrificed and viral titers in 996 salivary glands and lungs of individual mice were determined by standard plaque 997 assays. To obtain high-dose systemic infection, BALB/c mice were inoculated i.p. with 998 10^6 PFU/mouse of MCMVwt or MCMV Δ m138 for 6 hours after which peritoneal 999 exudate cells were isolated according to Ray and Dittel (2010). At least two independent 1000 experiments were carried out for each subject of analysis. 1001

1002

1003 Adoptive transfer assay

C57BL/6 SCID mice were i.p. infected with 2x10⁵ PFU/mouse of MCMVwt or 1004 1005 MCMVAm138. One day prior to infection, mice were first injected i.p. with 250 µg of anti-mouse NK1.1 and a few hours later were given 10^5 M25-II CD4⁺ T cells. Another 1006 1007 NK cell depletion followed on day 3 post infection. Spleen, lungs and salivary glands were isolated 7 days after infection and the expansion of $CD4^+$ T cell ($CD45.1^+$ $CD4^+$) 1008 was analyzed. M25-II CD4⁺ T cells were obtained from naive C57BL/6 transgenic 1009 M25-II mice. Briefly, splenocytes from C57BL/6 M25-II mice were isolated and 1010 enriched using CD4⁺ T Cell Isolation Kit (Miltenyi). Percentage of M25-II CD4⁺ T cells 1011 was obtained by staining with TCR V alpha 11 (clone RR8-1, eBioscience 1012 1013 ThermoFisher) antibody.

1014

1015 *In vitro* stimulation of CD8⁺ T cells

1016 C57BL/6 BMDCs were infected with 3 PFU/cell of indicated viruses. After 24 hours of
1017 infection, splenocytes from naive Maxi mice were added at the different T:E

1018 (BMDCs:CD8⁺) ratios to infected BMDCs together with Brefeldin A (eBioscience, 1019 Thermo Fisher Scientific). After 6 hours of co-cultivation, IFN- γ production by CD8⁺ T 1020 cells was measured. At least three independent experiments were carried out for each 1021 subject of analysis with two technical replicates/experiment.

1022

1023 Quantification of serum anti-MCMV antibody levels

1024 Detection of antibodies against MCMV on sera of MCMV-infected mice was performed by sandwich ELISA using 1.5 µg/well of MCMVAm138-infected MEF lysate to coat 1025 the ELISA plates as described in Miletic et al., 2017. Briefly, 5x10⁶ MEFs were 1026 1027 infected with 0.01 PFU/cell with MCMVAm138 until a high infection was reached after 1028 5 days. Cells were then harvested by incubation with 2 mM EDTA and washed twice with cold PBS. Cells were sonicated in bicarbonate buffer, quantified by BCA and 1029 1030 stored at -20°C. Diluted sera were incubated for 2 hours on the coated plates, followed by incubation with anti-mouse IgG-HRP to measure total IgGs, or with anti-mouse 1031 IgG1, IgG2a, IgG2b, IgG3 or IgM biotin conjugated (Jackson ImmunoResearch), 1032 followed by streptavidin-HRP. After washing, freshly prepared TMB substrate solution 1033 was added and the absorbance was measured at 450 and 570 nm wavelength (Thermo 1034 1035 Scientific Multiskan FC). At least two independent experiments were carried out for each subject of analysis with at least two technical replicates/experiment. 1036

1037

1038 In vitro neutralization

1039 Collected sera from MCMV infected mice were decomplemented at 56°C for 30 1040 minutes, and then incubated, at the indicated dilution, with 100 PFU of the MCMV-1041 GFP in DMEM containing or not 25% of rabbit serum for 1 hour at 37°C. The mixtures 1042 were then transferred to monolayers of MEFs p53 grown in wells of 24-well plates, and 1043 further incubated 1 hour at 37°C. Next, cells were covered with medium containing 1044 0.25% agarose and lysis plaques produced after 5-7 days in each condition counted. 1045 Results were represented as the percentage of plaque reduction, determined by the ratio 1046 of the amount of the plaques counted in the sample wells relative to the amount of 1047 plaques visualized in wells containing the serum of an uninfected mouse. At least two 1048 independent experiments were carried out for each subject of analysis with at least three 1049 technical replicates/experiment.

1050

1051 Statistical analyses

1052 Results are expressed as mean +/- standard deviation (SD) or standard error of the mean (SEM) of at least three independent experiments. For in vivo experiments, mice were 1053 pooled and randomized in experimental groups from 4 to 6 animals. The sample size 1054 1055 was determined by pilot studies and according to the accepted practices in previous literature using the MCMV model. The selection of the appropriate statistical test was 1056 1057 based on the number and distribution of data points per set. Differences between group means or individual values were assessed using the unpaired two-tailed *t*-test. Statistical 1058 differences between more than two study groups were evaluated using either the one-1059 1060 way ANOVA test or the Kruskal-Wallis bidirectional test. Exact p-values considered statistically significant and statistical details of experiments are indicated in the figure 1061 legends. All statistical analyses were performed using GraphPad Prism software version 1062 1063 7.03 and 8.1.1.

1064

1065 The key Resources Table (Supplementary File 1) lists the key reagents used in this1066 study.

1067 Acknowledgements

1068 We thank Adriana Lázaro for technical assistance with the production of the monoclonal antibody against m138, Manuel Eduardo Sáez Moya for help in the 1069 1070 preparation of histological tissue sections, and Francesc Poblador and Pablo Hernández-Luis for technical assistance in the immunohistochemistry assays. We acknowledge the 1071 use of the Advanced Optical Microscopy Facility at the University of Barcelona, and 1072 1073 María Calvo for the analysis of confocal fluorescence microscopy images. We also 1074 thank Antonio Alcamí (Autonomous University of Madrid, Spain) for providing HSV-1 and HSV-2 expressing GFP. In addition, we would like to thank Lea Hiršl, Tina Jenuš 1075 and Maja Cokarić Brdovčak for the help involving adoptive transfer assay and 1076 genotyping of C57BL/6 M25-II mice. 1077

1078

1079 Competing interests

1080 No competing interests declared.

1081

1082 Funding

The study was supported by the Ministerio de Economia y Competitividad (MINECO, 1083 Spain) through grants SAF 2017-87688 (to Angulo A.), and RTI2018-094440-B-I00 (to 1084 Engel P.), by the grant "Strengthening the capacity of CerVirVac for research in virus 1085 immunology and vaccinology", KK.01.1.1.01.0006, awarded to the Scientific Centre of 1086 Excellence for Virus Immunology and Vaccines and co-financed by the European 1087 1088 Regional Development Fund (to Jonjic S.), by the University of Rijeka under the project number uniri-biomed-18-170 (to Krmpotić A.), by the Croatian-Swiss Research 1089 Program of the Croatian Science Foundation and the Swiss National Science 1090 Foundation with funds obtained from the Swiss-Croatian Cooperation Programme (to 1091

- 1092 Oxenius A. and Krmpotić A.), and by the Deutsche Forschungsgemeinschaft (DFG,
- 1093 German Research Foundation) Projektnummer 421451057 FOR2830 (to Messerle
- 1094 M. and Jonjic S.) and HE2526/9-1 (to Hengel H.). Angulo G., and Puñet-Ortiz J. were
- supported by a Formación de Personal Investigador fellowship (MINECO).

- 1096 **References**
- 1097

1098 Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, Magaletti D,
1099 Buckwalter S, Ledbetter JA, Clark EA. Characterization of human inducible
1100 costimulator ligand expression and function. J Immunol. 2000;164(9):4689-96. DOI:
1101 <u>10.4049/jimmunol.164.9.4689</u>

Arapović J, Lenac Rovis T, Reddy AB, Krmpotić A, Jonjić S. Promiscuity of MCMV
immunoevasin of NKG2D: m138/fcr-1 down-modulates RAE-1epsilon in addition to

 1105
 MULT-1
 and
 H60.
 Mol
 Immunol.
 2009;47(1):114-22.
 DOI:

 1106
 10.1016/j.molimm.2009.02.010

1107

Arens R, Loewendorf A, Her MJ, Schneider-Ohrum K, Shellam GR, Janssen E, Ware
CF, Schoenberger SP, Benedict CA. B7-mediated costimulation of CD4 T cells
constrains cytomegalovirus persistence. J Virol. 2011;85(1):390-6.
DOI:<u>10.1128/JVI.01839-10</u>

1112

Bertram EM, Tafuri A, Shahinian A, Chan VS, Hunziker L, Recher M, Ohashi PS, Mak
TW, Watts TH. Role of ICOS versus CD28 in antiviral immunity. Eur J Immunol.
2002;32(12):3376-85.DOI:10.1002/1521-4141(200212)32:12<3376::AID-

1116 <u>IMMU3376>3.0.CO;2-Y</u>

1117

Brinkmann MM, Dağ F, Hengel H, Messerle M, Kalinke U, Čičin-Šain L.
Cytomegalovirus immune evasion of myeloid lineage cells. Med Microbiol Immunol.

1120 2015;204(3):367-82. DOI:<u>10.1007/s00430-015-0403-4</u>

Brune W, Wagner M, Messerle M. Manipulating cytomegalovirus genomes by BAC
mutagenesis: Strategies and applications, *in* Reddehase, M.J. (*ed.*) Cytomegaloviruses,
Molecular Biology and Immunology. (Vol. 1). Caister Academic Press. Norfolk, UK.
2006;63-89.

1126

Budt M, Reinhard H, Bigl A, Hengel H. Herpesviral Fcgamma receptors: culprits
attenuating antiviral IgG? Int Immunopharmacol. 2004;4(9):1135-48.
DOI:10.1016/j.intimp.2004.05.020

1130

Cavanaugh VJ, Stenberg RM, Staley TL, Virgin HW 4th, MacDonald MR, Paetzold S,
Farrell HE, Rawlinson WD, Campbell AE. Murine cytomegalovirus with a deletion of
genes spanning HindIII-J and -I displays altered cell and tissue tropism. J Virol.
1996;70(3):1365-74.

1135

Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition.
Nat Rev Immunol. 2013;13(4):227-42. DOI:<u>10.1038/nri3405</u>

1138

Choi YS, Kageyama R, Eto D, Escobar TC, Johnston RJ, Monticelli L, Lao C, Crotty S.
ICOS receptor instructs T follicular helper cell versus effector cell differentiation via
induction of the transcriptional repressor Bcl6. Immunity. 2011;34(6):932-46.
DOI:<u>10.1016/j.immuni.2011.03.023</u>

1144 Clement M, Marsden M, Stacey MA, Abdul-Karim J, Gimeno Brias S, Costa Bento D,

1145 Scurr MJ, Ghazal P, Weaver CT, Carlesso G, Clare S, Jones SA, Godkin A, Jones GW,

1146	Humphreys IR. Cytomegalovirus-specific IL-10-Producing CD4+ T Cells are governed
1147	by type-I IFN-induced IL-27 and promote virus persistence. PLoS Pathog.
1148	2016;12(12):e1006050. DOI: 10.1371/journal.ppat.1006050
1149	
1150	Corrales-Aguilar E, Hoffmann K, Hengel H. CMV-encoded Fcy receptors: modulators
1151	at the interface of innate and adaptive immunity. Semin Immunopathol.
1152	2014;36(6):627-40.
1153	DOI: <u>10.1007/s00281-014-0448-2</u>
1154	
1155	Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Klages S, et al.
1156	Guidelines for the use of flow cytometry and cell sorting in immunological studies
1157	(second edition). Eur J Immunol. 2019;49(10):1457-973. DOI:10.1002/eji.201970107
1158	
1159	Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, Manning S, Nguyen T, Burwell T,
1160	Schneider H, Gonzalo JA, Gosselin M, Owen LR, Rudd CE, Gutierrez-Ramos JC. The
1161	CD28-related molecule ICOS is required for effective T cell-dependent immune
1162	responses. Immunity. 2000;13(1):95-105. DOI:10.1016/s1074-7613(00)00011-x
1163	
1164	Crnković-Mertens I, Messerle M, Milotić I, Szepan U, Kucić N, Krmpotić A, Jonjić S,
1165	Koszinowski UH. Virus attenuation after deletion of the cytomegalovirus Fc receptor
1166	gene is not due to antibody control. J Virol. 1998;72(2):1377-82.
1167	
1168	Engel P, Pérez-Carmona N, Albà MM, Robertson K, Ghazal P, Angulo A. Human
1169	cytomegalovirus UL7, a homologue of the SLAM-family receptor CD229, impairs
1170	cytokine production. Immunol Cell Biol. 2011;89(7):753-66. DOI:10.1038/icb.2011.55

1173	Suárez NM, Davies JA, Antrobus R, Stanton RJ, Aicheler RJ, Nichols H, Vojtesek B,
1174	Trowsdale J, Davison AJ, Gygi SP, Tomasec P, Lehner PJ, Wilkinson GW. Control of
1175	immune ligands by members of a cytomegalovirus gene expansion suppresses natural
1176	killer cell activation. Elife. 2017;6. pii: e22206. DOI: 10.7554/eLife.22206
1177	
1178	Fink A, Renzaho A, Reddehase MJ, Lemmermann NA. The p36 isoform of murine
1179	cytomegalovirus m152 protein suffices for mediating innate and adaptive immune
1180	evasion. Viruses. 2013;5(12):3171-91. DOI: <u>10.3390/v5123171</u>
1181	
1182	Fleming P, Davis-Poynter N, Degli-Esposti M, Densley E, Papadimitriou J, Shellam G,
1183	Farrell H. The murine cytomegalovirus chemokine homolog, m131/129, is a
1184	determinant of viral pathogenicity. J Virol. 1999;73(8):6800-9. DOI:
1185	10.1128/JVI.73.8.6800-6809.1999
1186	
1187	Gewurz BE, Vyas JM, Ploegh HL. Herpesvirus evasion of T-cell immunity. In: Arvin
1188	A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K,
1189	editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge:
1190	Cambridge University Press. 2007. Chapter 62. PubMed PMID: 21348103.
1191	
1192	Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of immature
1193	and mature Langerhans cell-type dendritic cells to infection and immunomodulation by
1194	human cytomegalovirus. J Virol. 2003;77(13):7563-74. DOI:10.1128/jvi.77.13.7563-
1195	7574.2003

Fielding CA, Weekes MP, Nobre LV, Ruckova E, Wilkie GS, Paulo JA, Chang C,

1	1	۵	6
_		.)	υ

Hudson JB. Further studies on the mechanism of centrifugal enhancement of
cytomegalovirus infectivity. J Virol Methods. 1988;19(2):97-108. DOI:<u>10.1016/0166-</u>
0934(88)90153-x

1200

Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I,
Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally
related to CD28. Nature. 1999;397(6716):263-6. DOI:<u>10.1038/16717</u>

1204

Hutloff A. Regulation of T follicular helper cells by ICOS. Oncotarget.
2015;6(26):21785-6. DOI: <u>10.18632/oncotarget.4798</u>

1207

1208 Khan N, Gowthaman U, Pahari S, Agrewala JN. Manipulation of costimulatory
1209 molecules by intracellular pathogens: veni, vidi, vici!! PLoS Pathog.
1210 2012;8(6):e1002676. DOI:10.1371/journal.ppat.1002676

1211

1212 Khayyamian S, Hutloff A, Büchner K, Gräfe M, Henn V, Kroczek RA, Mages HW.

1213 ICOS-ligand, expressed on human endothelial cells, costimulates Th1 and Th2 cytokine

secretion by memory CD4+ T cells. Proc Natl Acad Sci U S A. 2002;99(9):6198-203.

1215 DOI:<u>10.1073/pnas.092576699</u>

1216

Kopf M, Coyle AJ, Schmitz N, Barner M, Oxenius A, Gallimore A, Gutierrez-Ramos
JC, Bachmann MF. Inducible costimulator protein (ICOS) controls T helper cell subset
polarization after virus and parasite infection. J Exp Med. 2000;192(1):53-61.
DOI:<u>10.1084/jem.192.1.53</u>

1222 Krmpotić A, Messerle M, Crnkovic-Mertens I, Polic B, Jonjic S, Koszinowski UH. The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects 1223 the virus against T cell control in vivo. J Exp Med. 1999;190(9):1285-96. 1224 DOI: 10.1084/jem.190.9.1285 1225 1226 Lenac T, Budt M, Arapović J, Hasan M, Zimmermann A, Simic H, Krmpotic A, 1227 Messerle M, Ruzsics Z, Koszinowski UH, Hengel H, Jonjic S. The herpesviral Fc 1228 receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60. J Exp Med. 1229 1230 2006;203(8):1843-50. DOI:10.1084/jem.20060514 1231 Liu D, Xu H, Shih C, Wan Z, Ma X, Ma W, Luo D, Qi H. T-B-cell entanglement and 1232 1233 ICOSL-driven feed-forward regulation of germinal centre reaction. Nature. 2015;517(7533):214-8. DOI:10.1038/nature13803 1234 1235 Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier 1236 LL. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired 1237 1238 by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med. 2003;197(10):1245-53. DOI:10.1084/jem.20021973 1239 1240 1241 Loewendorf A, Krüger C, Borst EM, Wagner M, Just U, Messerle M. Identification of a 1242 mouse cytomegalovirus gene selectively targeting CD86 expression on antigenpresenting cells. J Virol. 2004;78(23):13062-71. DOI: 10.1128/JVI.78.23.13062-1243

1245

1244

13071.2004

1246	Mandaric S, Walton SM, Rülicke T, Richter K, Girard-Madoux MJ, Clausen BE,
1247	Zurunic A, Kamanaka M, Flavell RA, Jonjic S, Oxenius A. IL-10 suppression of
1248	NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged
1249	MCMV persistence. PLoS Pathog. 2012;8(8):e1002846. DOI:
1250	10.1371/journal.ppat.1002846
1251	
1252	Mathys S, Schroeder T, Ellwart J, Koszinowski UH, Messerle M, Just U. Dendritic cells
1253	under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and
1254	to restrict T cell activation. J Infect Dis. 2003;187(6):988-99. DOI:10.1086/368094
1255	
1256	Miletic A, Lenartic M, Popovic B, Brizic I, Trsan T, Miklic K, Mandelboim O,
1257	Krmpotic A, Jonjic S. NCR1-deficiency diminishes the generation of protective murine
1258	cytomegalovirus antibodies by limiting follicular helper T-cell maturation. Eur J
1259	Immunol. 2017;47(9):1443-56. DOI:10.1002/eji.201646763
1260	
1261	Mintern JD, Klemm EJ, Wagner M, Paquet ME, Napier MD, Kim YM, Koszinowski
1262	UH, Ploegh HL. Viral interference with B7-1 costimulation: a new role for murine
1263	cytomegalovirus fc receptor-1. J Immunol. 2006;177(12):8422-31.

- 1264 DOI:<u>10.4049/jimmunol.177.12.8422</u>
- 1265

Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits
maturation and impairs function of monocyte-derived dendritic cells. Blood.
2002;99(8):2913-21. DOI:<u>10.1182/blood.v99.8.2913</u>

1269

1270	Ogasawara K, Yoshinaga SK, Lanier LL. Inducible costimulator costimulates cytotoxic
1271	activity and IFN-gamma production in activated murine NK cells. J Immunol.
1272	2002;169(7):3676-85. DOI: <u>10.4049/jimmunol.169.7.3676</u>

- 1274 Pérez-Carmona N, Farré D, Martínez-Vicente P, Terhorst C, Engel P, Angulo A.1275 Signaling lymphocytic activation molecule family receptor homologs in new world
- 1276 monkey cytomegaloviruses. J Virol. 2015;89:11323-36. DOI:<u>10.1128/JVI.01296-15</u>

1277

- Qian X, Agematsu K, Freeman GJ, Tagawa Y, Sugane K, Hayashi T. The ICOS-ligand
 B7-H2, expressed on human type II alveolar epithelial cells, plays a role in the
 pulmonary host defense system. Eur J Immunol. 2006;36(4):906-18.
- 1281 DOI:<u>10.1002/eji.200535253</u>

1282

Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010;(35):1488.
DOI:10.3791/1488

1285

1286 Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, Gregson BP, June CH,

1287 Linsley PS. Modulation of TCR-induced transcriptional profiles by ligation of CD28,

1288 ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A. 2002;99(18):11790-5.

- 1289 DOI:<u>10.1073/pnas.162359999</u>
- 1290
- 1291 Roussel L, Landekic M, Golizeh M, Gavino C, Zhong MC, Chen J, Faubert D,
- 1292 Blanchet-Cohen A, Dansereau L, Parent MA, Marin S, Luo J, Le C, Ford BR, Langelier
- 1293 M, King IL, Divangahi M, Foulkes WD, Veillette A, Vinh DC. Loss of human ICOSL
- results in combined immunodeficiency. J Exp Med. 2018;215(12):3151-64.

- 1295 DOI:10.1084/jem.20180668
- 1296

Schepp J, Chou J, Skrabl-Baumgartner A, Arkwright PD, Engelhardt KR, Hambleton S,
Morio T, Röther E, Warnatz K, Geha R, Grimbacher B. 14 Years after discovery:
clinical follow-up on 15 patients with inducible co-stimulator deficiency. Front
Immunol. 2017;8:964. DOI:10.3389/fimmu.2017.00964

- 1301
- 1302 Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch
- 1303 S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K,
- 1304 Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis.
- 1305 Nat Methods. 2012 28;9(7):676-82. DOI: <u>10.1038/nmeth.2019</u>
- 1306
- Schuren AB, Costa AI, Wiertz EJ. Recent advances in viral evasion of the MHC Class I
 processing pathway. Curr Opin Immunol. 2016;40:43-50.
 DOI:10.1016/j.coi.2016.02.007
- 1310
- 1311 Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(2):116-
- 1312 26. DOI:<u>10.1038/nri727</u>
- 1313
- 1314 Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229(1):5-11.
 1315 DOI: <u>10.1111/j.1600-065X.2009.00784.x</u>
- 1316
- 1317 Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H,
- 1318 Koszinowski U, Brune W, Adler B. Cloning and sequencing of a highly productive,

- endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen
 Virol. 2008;89(Pt 2):359-68. DOI:10.1099/vir.0.83286-0
- 1321

1322	Stahl FR, Keyser KA, Heller K, Bischoff Y, Halle S, Wagner K, Messerle M, Förster R.
1323	Mck2-dependent infection of alveolar macrophages promotes replication of MCMV in
1324	nodular inflammatory foci of the neonatal lung. Mucosal Immunol. 2015;8(1):57-
1325	67. DOI: <u>10.1038/mi.2014.42</u>
1326	
1327	Stempel M, Chan B, Juranić Lisnić V, Krmpotić A, Hartung J, Paludan SR, Füllbrunn

- 1328 N, Lemmermann NA, Brinkmann MM. The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-kB signaling and STING's dual 1329 EMBO J. role during MCMV infection. 2019;38(5). pii: e100983. 1330 1331 DOI:10.15252/embj.2018100983
- 1332

1333 Strazic Geljic I, Kucan Brlic P, Angulo G, Brizic I, Lisnic B, Jenus T, Juranic Lisnic V,

1334 Pietri GP, Engel P, Kaynan N, Zeleznjak J, Schu P, Mandelboim O, Krmpotic A,

1336 protein-1 compartment mediating broad-spectrum immune evasion. Elife. 2020;9. pii:

Angulo A, Jonjic S, Lenac Rovis T. Cytomegalovirus protein m154 perturbs the adaptor

- 1337 e50803. DOI:10.7554/eLife.50803
- 1338
- 1339 Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and
 1340 B7.2, is induced by TNFalpha. Immunity. 1999;11(4):423-32. DOI:<u>10.1016/s1074-</u>
 1341 <u>7613(00)80117-x</u>
- 1342

1343	Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee
1344	SK, Mizutani S, Morio T. Impaired CD4 and CD8 effector function and decreased
1345	memory T cell populations in ICOS-deficient patients. J Immunol. 2009;182(9):5515-
1346	27.
1347	DOI: <u>10.4049/jimmunol.0803256</u>
1348	
1349	Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, Elliot D, Weinstock J, Matis
1350	LA, Bluestone JA, Sperling AI. Inducible costimulator regulates Th2-mediated
1351	inflammation, but not Th2 differentiation, in a model of allergic airway disease. J
1352	Immunol. 2001;167(4):1996-2003. DOI:10.4049/jimmunol.167.4.1996
1353	
1354	Thäle R, Lucin P, Schneider K, Eggers M, Koszinowski UH. Identification and
1355	expression of a murine cytomegalovirus early gene coding for an Fc receptor. J Virol.
1356	1994;68(12):7757-65.
1357	
1358	Torti N, Walton SM, Brocker T, Rülicke T, Oxenius A. 2011. Non-hematopoietic cells
1359	in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus
1360	infection. PLoS Pathog. 2011;7:e1002313. DOI: <u>10.1371/journal.ppat.1002313</u>

Trgovcich J, Stimac D, Polić B, Krmpotić A, Pernjak-Pugel E, Tomac J, Hasan M,
Wraber B, Jonjić S. Immune responses and cytokine induction in the development of
severe hepatitis during acute infections with murine cytomegalovirus. Arch Virol.
2000;145(12):2601-18. DOI:<u>10.1007/s007050070010</u>

1367	Wagner M, Jonjic S, Koszinowski UH, Messerle M. Systematic excision of vector
1368	sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J
1369	Virol. 1999;73(8):7056-60.

Wallin JJ, Liang L, Bakardjiev A, Sha WC. Enhancement of CD8+ T cell responses by
ICOS/B7h costimulation. J Immunol. 2001;167(1):132-9.
DOI:<u>10.4049/jimmunol.167.1.132</u>

1374

1375 Welten SPM, Redeker A, Toes REM, Arens R. Viral persistence induces antibody

1376 inflation without altering antibody avidity. J Virol. 2016;90(9):4402-11.
1377 DOI:<u>10.1128/JVI.03177-15</u>

1378

Wikenheiser DJ, Stumhofer JS. ICOS Co-Stimulation: Friend or Foe? Front Immunol.
2016;7:304. DOI:<u>10.3389/fimmu.2016.00304</u>

1381

1382 Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang

1383 M, Coccia MA, Kohno T, Tafuri-Bladt A, Brankow D, Campbell P, Chang D, Chiu L,

1384 Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL,

1385 Van G, Mak TW, Senaldi G. T-cell co-stimulation through B7RP-1 and ICOS. Nature.

1386 1999;402(6763):827-32. DOI:<u>10.1038/45582</u>

1387

1388 Yoshinaga SK, Zhang M, Pistillo J, Horan T, Khare SD, Miner K, Sonnenberg M,

1389 Boone T, Brankow D, Dai T, Delaney J, Han H, Hui A, Kohno T, Manoukian R,

1390 Whoriskey JS, Coccia MA. Characterization of a new human B7-related protein: B7RP-

1 is the ligand to the co-stimulatory protein ICOS. Int Immunol. 2000;12(10):1439-47.

1392 DOI:<u>10.1093/intimm/12.10.1439</u>

- Zarama A, Pérez-Carmona N, Farré D, Tomic A, Borst EM, Messerle M, Jonjic S,
 Engel P, Angulo A. Cytomegalovirus m154 hinders CD48 cell-surface expression and
 promotes viral escape from host natural killer cell control. PLoS Pathog.
 2014;10(3):e1004000. DOI:<u>10.1371/journal.ppat.1004000</u>
- 1399 Železnjak J, Lisnić VJ, Popović B, Lisnic B, Babic M, Halenius A, L'Hernault A, Lenac
- 1400 Rovis A, Hengel H, Erhard F, Redwood AJ, Vidal SM, Dölken L, Krmpotić A, Jonjic
- 1401 S. The complex of MCMV proteins and MHC class I evades NK cell control and drives
- the evolution of virus-specific activating Ly49 receptors. J Exp Med. 2019;216(8):1809-
- 1403 27. DOI: <u>10.1084/jem.20182213</u>
- 1404
- 1405 Ziegler H, Thale R, Lucin P, Muranyi W, Flohr T, Hengel H, Farrell H, Rawlinson W,
- 1406 Koszinowski UH. A mouse cytomegalovirus glycoprotein retains MHC class I
- 1407 complexes in the ERGIC/cis-Golgi compartments. Immunity. 1997;6(1):57-66. DOI:
- 1408 <u>10.1016/s1074-7613(00)80242-3</u>

1409 Figure legends

1410

Figure 1. Downregulation of ICOSL upon MCMV infection of APCs. (A) Peritoneal 1411 1412 macrophages (M Φ) were mock-infected or infected for 72 hours with MCMV-GFP at an moi of 5 and analyzed by flow cytometry for surface expression of ICOSL, MHC I, 1413 or CD62L using specific mAbs against each of these molecules. Grey histograms 1414 1415 represent the expression on mock-infected cells, green histograms represent the expression on MCMV-infected (GFP+) cells, and blue histograms represent the 1416 expression on uninfected (GFP-) cells from the same culture. (B) Bone marrow derived-1417 macrophages (BMM), bone marrow derived-dendritic cells (BMDC), IC-21, DC2.4, 1418 and SVEC4-10 cells were infected with MCMV-GFP at different moi (10, 20, 20, and 1419 1420 5, respectively) to obtain an infection of around 50% of the cell culture, and analyzed by flow cytometry for surface expression of ICOSL. Grey, green, and blue histograms, as 1421 1422 indicated in A. (C) Same as in A, except that peritoneal macrophages were infected with 1423 MCMV-GFP at an moi of 10, or treated for 72 h with the same amount of MCMV-GFP UV-inactivated. Grey and green as indicated in A, and red histograms represent the 1424 expression on MCMV-GFP UV-inactivated infected cells. (D) Peritoneal macrophages, 1425 1426 BMDCs, and IC-21 cells were mock-infected (time 0) or infected with MCMV-GFP at an moi of 10, 40 and 20, respectively, and analyzed by flow cytometry for surface 1427 1428 expression of ICOSL at the different time points after infection indicated. In A, B, C, and D, the isotype for each antibody was used as a negative control (dotted lines). Data 1429 1430 are representative of at least two independent experiments.

1431

Figure 2. Identification of the MCMV gene involved in the decreased cell surface
expression of ICOSL. (A) IC-21 cells were mock-infected or infected for 72 h with

MCMV-GFP, MCMV-GFPAm128-m138, or MCMV-GFPAm1-m17 at an moi of 10 1434 1435 and examined by flow cytometry for surface expression of ICOSL. Grey histograms represent the expression of mock-infected cells, green histograms represent the 1436 1437 expression on MCMV-infected (GFP+) cells, and blue histograms represent the expression on uninfected (GFP-) cells from the same culture. (B) IC-21 cells were 1438 mock-infected or infected with MCMVwt or MCMVAm138 for 72h at an moi of 20 and 1439 1440 analyzed by flow cytometry for surface expression of ICOSL and CD84. Grey histograms as indicated in A, and brown histograms represent the expression on 1441 MCMVwt and MCMVAm138 IC-21 infected cells. (C) IC-21 cells were mock-1442 1443 transfected or transfected with the m138-GFP construct or with the control GFP empty 1444 vector and stained with the anti-ICOSL mAb or an isotype control (dotted lines). Dark green and red histograms represent cells from transfected cultures expressing or not 1445 1446 expressing GFP, respectively, and grey histograms represent surface expression of ICOSL on untransfected cells. In A, B, and C, the isotype for each antibody was used as 1447 1448 a negative control (dotted lines). Data are representative of at least two independent experiments. 1449

1450

1451 Figure 3. Localization of m138 in MCMV infected cells. (A) NIH3T3 cells were infected with MCMV-GFP at an moi of 5 for 24 h, fixed with 4% formaldehyde (panels 1452 d-f) or fixed and permeabilized with 0.05% Triton (panels a-c and g), and stained with 1453 1454 the anti-m138 mAb followed by an anti-mouse IgG-A555. Nuclei were stained with the DAPI reagent. The cells were examined under a fluorescence microscope. 1455 1456 Magnification, x20 (a-f); an enlarged individual cell from panel c is shown in panel g. (B) MCMVwt-infected NIH3T3 cells were examined by flow cytometry for surface 1457 expression of m138 with the anti-m138 mAb (red histogram). Dotted line represents the 1458

isotype control. (C) 300.19 cells untransfected or stably transfected with the HA-m138 1459 1460 construct were fixed with 4% formaldehyde and stained with the anti-m138 mAb and DAPI and examined under a fluorescence microscope as indicated in A. Magnification, 1461 1462 x20. Overlaid images are shown. Transfected cells from the same cultures were analyzed by flow cytometry (right panels) with the anti-m138 mAb (red histogram), an 1463 1464 anti-HA mAb (grey histogram) or isotype controls (dotted lines). (D) NIH3T3 cells 1465 were infected with MCMV at an moi of 5 for 24 h, treated with LysoTracker DND99, fixed with 4% formaldehyde and permeabilized with 0.02% Saponin, and stained with 1466 the anti-m138 mAb followed by an anti-mouse IgG-A488. Nuclei were stained with the 1467 1468 DAPI reagent. The cells were examined under a confocal microscope. Representative fields are shown in panels a, b, and c, with an enlargement of an individual and more 1469 1470 exposed cell from panel c, in panel d. Magnification, x63.

1471 The online version of this article includes the following figure supplements for figure 3:

1472 Figure supplement 1. Localization of m138 in MCMV-infected DC2.4 cells.

1473

Figure 4. m138 leads to a reduction of the expression of ICOSL on the cell surface 1474 of infected cells but not of its overall intracellular levels. (A) NIH3T3 cells stably 1475 transfected with HA-ICOSL were mock-infected (grey histograms) or infected with 1476 MCMVwt or MCMV Δ m138 (brown or pink histograms, respectively) and analyzed by 1477 flow cytometry for surface expression of ICOSL and MHC I. (B) NIH3T3 HA-ICOSL 1478 1479 cells non-transfected (grey histograms) or transfected with the m138-GFP construct (green histograms) were analyzed by flow cytometry for surface expression of ICOSL 1480 and CD44. In A and B, the isotype for each antibody was used as a negative control 1481 (dotted lines). (C) NIH3T3 HA-ICOSL cells were mock-infected (lane 2), treated with 1482 trypsin (lane 3), or infected with MCMVwt (lane 4) or MCMV∆m138 (lane 5). 1483

Untransfected NIH3T3 cells were used as a control (lane 1). Samples were analyzed by 1484 1485 western blot using an anti-HA mAb, followed by anti-rabbit IgG-HRP. An anti-IE1 and an anti-actin mAbs followed by anti-mouse IgG-HRP, were used as controls of MCMV 1486 1487 infection and loading, respectively. (D) Flow cytometry analysis of NIH3T3 HA-ICOSL treated with trypsin (open histogram) or mock-treated (grey histogram) and 1488 stained with an anti-HA mAb or an isotype control (dotted line), followed by anti-1489 1490 mouse IgG PE. (E) NIH3T3 cells (lane 1) or NIH3T3 HA-ICOSL (lane 2) were surface labeled with biotin, immunoprecipitated with an anti-HA mAb, and analyzed by western 1491 blot analysis using streptavidin-HRP conjugate. (F) NIH3T3 HA-ICOSL cells were 1492 1493 mock-infected (lane 2), or infected with MCMVwt (lane 3) or MCMVwt UV-1494 inactivated (lane 4). Samples were lysed and processed as indicated in C. A lysate of 1495 untransfected NIH3T3 cells (lane 1) was also subjected to western blot and employed as 1496 a control. All infections were performed at an moi of 5 for 24 h. Data are representative of at least two independent experiments. In C, E, and F, the size of the bands 1497 1498 corresponding to ICOSL are indicated on the right margin in kilodaltons (kDa). In E, the sizes of the molecular weight markers are shown on the left side. 1499

1500

Figure 5. m138 impedes ICOSL maturation redirecting it to lysosomal 1501 1502 degradation. (A) Western blot analysis of NIH3T3 cells untransfected (lane 1) or 1503 transiently co-transfected with either the HA-ICOSL and the control-GFP (CTL-GFP) constructs (lanes 2 and 3), or the HA-ICOSL and the m138-GFP constructs (lanes 4 and 1504 1505 5) and, when indicated, treated with 250 µM of leupeptin and 20 nM of bafilomycin A1 (lanes 3 and 5). The expression of ICOSL and actin was assessed as described in Figure 1506 4C, and for the expression of the m138-GFP and CTL-GFP proteins a polyclonal 1507 antibody anti-GFP followed by anti-rabbit IgG-HRP were used. (B) NIH3T3 HA-1508

1509 ICOSL were infected with MCMVwt at an moi of 5 for 24 h in the absence (-; panels a, 1510 b, c and d) or presence of leupeptin and bafilomycin (panels e, f, g and h). Cells were fixed, permeabilized, and stained with anti-m138 and anti-ICOSL mAbs followed by an 1511 1512 anti-mouse IgG-A555 and anti-rat IgG-A488, respectively. Nuclei were stained with the 1513 DAPI reagent and samples were examined under a confocal fluorescence microscope. 1514 Shown are representative cells from cultures stained for m138 (panels a, e), ICOSL (b, 1515 f), and overlaid images (c, d, g, and h). Enlarged and more exposed individual cells from panels c and g are presented on panels d and h, respectively. Magnification, x63. 1516 (C) NIH3T3 HA-ICOSL infected and treated with the lysosomal inhibitors as in B were 1517 1518 fixed, permeabilized with the Foxp3 staining buffer set, and analyzed by flow cytometry with anti-m138 and anti-ICOSL mAbs followed by an anti-mouse IgG-A555 and anti-1519 rat IgG-A488, respectively. Conditions were analyzed in triplicates and median 1520 1521 fluorescence intensity (MFI) values +/- SD were extracted from pre-gated m138 positive cells. (D) NIH3T3 cells were co-transfected with the m138-GFP and HA-1522 1523 ICOSL constructs. HA-ICOSL was immunoprecipitated from 0.5% Triton treated lysates using an anti-HA mAb or an anti-hFc as a control. Recovered 1524 1525 immunoprecipitates were subjected to SDS-PAGE and western blotting with antibodies 1526 against GFP and HA, as described in A and Figure 4C. Data are representative of at least two independent experiments. In A and D, the size of the two bands corresponding 1527 to ICOSL, and in D, the band corresponding to m138-GFP, are indicated on the right 1528 1529 margin in kilodaltons (kDa). In A and D, the sizes of the molecular weight markers are shown on the left side. 1530

1531

Figure 6. Identification of the m138 domains involved in the downmodulation of
ICOSL and CD80. (A) Schematic representation (not drawn to scale) of m138-GFP

protein mutants. NIH3T3 ICOSL-HA cells were untransfected or transfected with 1534 1535 m138-GFP, or m138-GFP mutant constructs and analyzed by flow cytometry for ICOSL and CD80 surface levels. Panels on the right represent the MFI of each sample 1536 1537 minus the MFI of the control isotypes. Grey histograms represent the expression of untransfected cells and colored histograms represent the expression of cells transfected 1538 with m138-GFP (green), m138AIg1-GFP (brown), m138AIg2-GFP (blue), or 1539 1540 m138 Δ Ig2/3-GFP (red). The isotype for each antibody was used as a negative control (dotted lines). A representative experiment out of two performed is shown. 1541

1542

1543 Figure 7. m138 is capable to restrict CD8⁺ T-cell activation by downregulating ICOSL on the surface of APCs. (A) C57BL/6 derived BMDCs were mock-infected or 1544 infected for 24 hours with MCMVwt or MCMVm138 mutants at an moi of 3 and 1545 1546 analyzed by flow cytometry for surface expression of ICOSL and CD80 using specific mAbs against each of these molecules. Grey histograms represent the expression of 1547 mock-infected cells and colored histograms represent the expression of cells infected 1548 (positive for the MCMV m04 protein) with MCMVwt (yellow), MCMVAm138 (pink), 1549 MCMVm138 Δ Ig2 (blue), or MCMVm138 Δ Ig2/3 (red). The isotype for each antibody 1550 1551 was used as a negative control (black line histograms). Panels on the right represent the MFI of each sample minus the MFI of the control isotypes. Results are representative of 1552 1553 two independent experiments (B) On the left, schematic representation of the in vitro 1554 antigen-presentation assay. BMDCs infected as indicated in A with MCMVwt (yellow), MCMVAm138 (pink), MCMVm138AIg2 (blue), or MCMVm138AIg2/3 (red), or left 1555 uninfected (grey) were further co-cultured with naïve CD8⁺ T cells from Maxi mice. 1556 After 6 h, IFN- γ production by CD8⁺ T cells was determined by flow cytometry. Results 1557

are representative of three independent experiments. Results are expressed as the mean

1559 +/-SEM of the percentage values obtained for samples in each group.

1560

Figure 8. Via targeting ICOSL, m138 reduces T-cell mediated control of MCMV 1561 **infection** *in vivo*. (A) BALB/c mice were intraperitoneally (i.p.) inoculated with $2x10^6$ 1562 1563 PFU MCMV-GFP. 2 days post infection mice were sacrificed and peritoneal exudate 1564 cells were extracted and analyzed by flow cytometry for surface expression of ICOSL and MHCI, using specific mAbs against each of these molecules. Blue histograms 1565 represent the expression of uninfected (GFP-) cells and green histograms represent the 1566 1567 expression of MCMV-infected (GFP+) cells from the same mouse. The isotype for each 1568 antibody was used as a negative control (dotted lines). The results obtained from a representative infected mouse out of two are shown. (B) BALB/c mice (n=4/group) 1569 were mock-infected or i.p. infected with 1×10^6 PFU of MCMVwt or MCMV Δ m138. At 1570 six hpi, peritoneal exudate cells were extracted and surface expression of ICOSL and 1571 CD80 assessed by flow cytometry on the surface of DCs (CD11⁺ MHC II⁺ CD3⁻CD19⁻ 1572 NKp46⁻ cells), gating on m04 positive cells when derived from MCMVwt- or 1573 MCMVAm138-infected mice. Results are expressed as the mean +/-SD of the MFI 1574 1575 values obtained for samples from two independent experiments. (C) Table displaying the immunomodulatory effects of the different MCMVs on the cellular targets of m138. 1576 (D) On the top, a schematic representation of the MCMV Δ m138 and MCMVm138 Δ Ig2 1577 in vivo infection assay is shown. C57BL/6 mice (n=5-7/group) with or without NK, or 1578 NK, CD4⁺ and CD8⁺ T-cell depletion, as indicated, were intravenously (i.v.) inoculated 1579 with $2x10^5$ PFU/mouse of MCMVwt (yellow circles), MCMV Δ m138 (pink triangles) or 1580 MCMVm138AIg2 (blue triangles). At day 14 post infection mice were sacrificed and 1581 viral titers in salivary glands and lungs of individual mice were determined by standard 1582

plaque assays. Horizontal bars indicate the median values. The Kruskal-Wallis test was
used to assess statistical differences between experimental groups. *p<0.05, **p<0.01.
A representative experiment out of two performed is shown.

1586 The online version of this article includes the following figure supplements for figure 8:

1587 Figure supplement 1. m138 contributes to immune evasion of D4⁺ T cells in spleens

- 1588 and lungs of MCMV infected mice.
- 1589

Figure 9. Blockade of ICOSL reduces the frequency of particular lymphocyte 1590 subsets in the spleen and lymph nodes of MCMV infected mice. (A) BALB/c mice 1591 (n=11-12/group) were i.p. inoculated with $2x10^6$ PFU of MCMV Δ m138 and treated 1592 with (a-ICOSL) or without (CTL) 100 mg of anti-ICOSL mAb. At day 14 post 1593 infection mice were sacrificed, and spleens and lymph nodes were isolated and 1594 disaggregated. Cell suspensions were analyzed by flow cytometry using anti-mouse 1595 1596 CD3, CD4, CD8, CD44, CD62L, CXCR5 and PD1 for T-cell phenotype. For B cell phenotype B220, CD21, CD23, CD95 and GL7 mAbs were used. Percentages of Tfh 1597 cells (CD3⁺CD4⁺CXCR5^{hi}PD1^{hi}), germinal center (GC) B cells (CD95^{hi}GL7^{hi}B220⁺), 1598 follicular (FO) B cells (CD21⁺CD23⁺B220⁺), and CD3⁺CD4⁺ or CD3⁺CD8⁺ naïve 1599 (CD44^{low}CD62L^{hi}) and memory (CD44^{hi}CD62L^{low}) T cells from these two organs are 1600 shown. (B) Representative immunofluorescence of spleens from mice infected and 1601 1602 treated with (panels b and d) or without (panels a and c) the anti-ICOSL mAb, as indicated in A. Two color colocalization with B220 in green and peanut agglutinin 1603 (PNA) in red are shown at x4 and x10 magnifications. Panels on the right show a 1604 1605 graphic representation of follicle and germinal center relative areas from tissue sections of a representative mouse of each experimental group. In graphs shown in A and B, 1606 results are expressed as mean +/- SD. Mice treated with anti-ICOSL mAb are 1607

represented as red squares and mice not receiving the mAb are represented as open circles. Two-tailed unpaired *t*-tests were used to assess statistical differences between experimental groups. p<0.05, p<0.01, p<0.001, p<0.001. Data are pooled from two independent experiments.

1612 The online version of this article includes the following figure supplements for figure 9:

1613 Figure supplement 1. Effect of ICOSL blockade on the frequency of several
1614 lymphocyte subsets in the spleen and lymph nodes of MCMV infected mice.

1615

Figure 10. ICOSL blockade limits the generation of MCMV specific antibodies. (A) 1616 Total levels of IgG, IgG1, IgG2a, IgG2b, IgG3 (at dilutions 1:200 and 1:400), and IgM 1617 (at dilutions 1:25 and 1:50) were determined by ELISA from sera collected at day 14 of 1618 1619 the same infected BALB/c mice indicated in Figure 8A. (B) Sera (at dilutions 1:10 and 1620 1:100) as in A were tested in a viral neutralization assay. Results are presented as the percentage of plaque reduction determined by the ratio of the number of plaques 1621 1622 counted in the sample wells relative to the ratio of plaques in wells containing the serum of an uninfected mouse used as a negative control. In A and B, results are expressed as 1623 mean +/- SD. Mice treated with anti-ICOSL mAb are represented as red squares and 1624 1625 mice that did not receive the mAb are represented as open circles. Two-tailed unpaired *t*-tests were used to assess statistical differences between experimental groups. *p<0.05, 1626 **p<0.01, ***p<0.001. Data are pooled from two independent experiments. 1627

1628 The online version of this article includes the following figure supplements for figure1629 10:

1630 Figure supplement 1. Effect of ICOSL blockade on MCMV neutralization in the
1631 presence of complement.

1632

Figure 11. HCMV, HSV-1, and HSV-2 also limit cell surface expression of ICOSL 1633 1634 on APCs. (A) Primary monocyte-derived macrophages (upper panels) and PMA-treated THP-1 cells (bottom panels) were mock-infected or infected for 72 hours with HCMV-1635 1636 GFP at an moi of 10 and analyzed by flow cytometry for cell-surface expression of human ICOSL or CD70 using specific mAbs against each of these receptors. Gray 1637 histograms represent the expression of mock-infected cells, green histograms represent 1638 1639 the expression on HCMV-infected (GFP+) cells, and blue histograms represent the expression on uninfected (GFP-) cells from the same culture. (B) PMA-treated THP-1 1640 cells were mock-infected (time 0) or infected with HCMV-GFP as in A and analyzed by 1641 1642 flow cytometry for surface expression of ICOSL at the different time points after infection indicated. (C) Same as in A, except that an moi of 20 was used, and THP-1 1643 1644 cells were also exposed for 72 h to the same amount of HCMV-GFP UV-inactivated 1645 (red histogram). (D) Equal amounts of lysates from PMA-treated THP-1 cells mockinfected (lane 1) or infected for 72 h at an moi of 20 with HCMV-GFP (lanes 2 and 3), 1646 1647 and when indicated, treated with 250 µM leupeptin and 20 nM of bafilomycin A1 (lane 3), were lysed and analyzed by western blot with antibodies against ICOSL and actin, 1648 followed by anti-rabbit IgG-HRP (ICOSL) or anti-mouse IgG-HRP (actin). (E) PMA-1649 treated THP-1 cells were mock-infected or infected with HSV-1-GFP, HSV-1-GFP UV-1650 inactivated, HSV-2-GFP or HSV-2-GFP UV-inactivated at an moi of 100 (HSV-1) or 1651 200 (HSV-2). 24 h later the expression of human ICOSL and CD70 were analyzed as in 1652 A. Green histograms represent the expression of ICOSL on infected cells, red 1653 histograms represent the expression on UV-inactivated HSV infected cells, and grey 1654 histograms represent the expression on mock-infected cells. The isotype for the ICOSL 1655 antibody was used as a negative control (dotted lines). A representative experiment out 1656 of three performed is shown. (F) PMA-treated THP-1 cells were mock-infected (lane 1) 1657

or infected with HSV-1-GFP (lane 2) and HSV-2-GFP (lane 3) as indicated in E. Cell
lysates were prepared, and subjected to western blot analysis using an anti-human
ICOSL or anti-actin mAbs as in D. The molecular weight of the band corresponding to
ICOSL is indicated in D and E in kilodaltons on the right margin.

1662

Figure 3-figure supplement 1. Localization of m138 in MCMV-infected DC2.4 cells. D2.4 cells were infected with MCMV-GFP at an moi of 5 for 24 h, fixed with 4% formaldehyde, permeabilized with 0.05% Triton, and stained with the anti-m138 mAb followed by an anti-mouse IgG-A555. Nuclei were stained with the DAPI reagent. The cells were examined under a fluorescence microscope. Magnification, x20 (a-c); an enlarged individual cell from panel c is shown in panel d.

1669

1670 Figure 8-figure supplement 1. m138 contributes to immune evasion of D4⁺ T cells in spleens and lungs of MCMV infected mice. On the top, a schematic representation 1671 of the adoptive transfer *in vivo* assay is shown. 1x10⁵ M25-specific transgenic CD4⁺ T 1672 cells were transferred (i.v.) into C57BL/6 SCID mice (n=4-5/group), which were 1673 depleted of NK cells as indicated, and either mock-infected or i.p. infected with $2x10^5$ 1674 PFU/mouse of MCMVwt or MCMVAm138. Seven dpi, spleens, lungs and salivary 1675 glands were harvested, and analyzed by flow cytometry using anti-CD45.1 and anti-1676 CD4 specific mAbs. The frequency of CD45.1⁺ CD4⁺ cells for each organ is indicated. 1677 Results are expressed as the mean +/-SEM of the percentage values obtained for 1678 1679 samples in each group.

1680

1681 Figure 9-figure supplement 1. Effect of ICOSL blockade on the frequency of 1682 several lymphocyte subsets in the spleen and lymph nodes of MCMV infected mice.


Cell suspensions obtained from spleens and lymph nodes of BALB/c mice infected and 1683 treated as indicated in Figure 8A were analyzed by flow cytometry using anti-mouse 1684 CD3, CD4, CD8, CD5, B220, CD23, CD21, CD138, and CD19 mAbs, and anti-mouse 1685 IgM polyclonal Ab. Percentages of total B cells (B220⁺), marginal zone (MZ) B cells 1686 (CD21⁺CD23⁻B220⁺), B1 B cells (CD19^{hi}B220^{int}), B1a (CD19^{hi}B220^{int}CD5⁺) and B1b 1687 (CD19^{hi}B220^{int}CD5⁻) subsets, CD3⁺CD4⁺ or CD3⁺CD8⁺ T cells, and plasma cells 1688 (CD138^{hi}B220^{low}CD19⁻IgM⁻) are shown. Results are expressed as mean +/- SD. Mice 1689 treated with anti-ICOSL mAb are represented as red squares and mice untreated are 1690 represented as open circles. Two-tailed unpaired t-test was used to assess statistical 1691 1692 differences between experimental groups.

1693


1694 Figure 10-figure supplement 1. Effect of ICOSL blockade on MCMV neutralization in the presence of complement. Same as in Figure 9B, except that the 1695 MCMV neutralization assay was performed in the presence of rabbit complement. 1696 Results are presented as the percentage of plaque reduction determined by the ratio of 1697 the number of plaques counted in the sample wells relative to the ratio of plaques in 1698 1699 wells containing the serum of an uninfected mouse used as a negative control. Results 1700 are expressed as mean +/- SD. Mice treated with anti-ICOSL mAb are represented as 1701 red squares and mice untreated are represented as empty circles. Two-tailed unpaired t-1702 test was used to assess statistical differences between experimental groups. *p<0.05, **p<0.01. 1703


1704

1705 Supplementary File 1. Key Resources Table.



ICOSL







Unpermeabilized

D

Permeabilized





300.19 HA-m138




m138


LysoTracker Merge d b С а











Α


















	NKG2D ligands			co-stimulatory molecules	
Viruses	MULT-1	RAE-Ιε	H60	ICOSL	CD80
MCMVwt (full lenght m138)	downregulated	downregulated	downregulated	downregulated	downregulated
MCMV∆m138 (m138 deleted)	not altered	not altered	not altered	not altered	not altered
MCMVm138∆lg2 (m138 lg2 domain deleted)	downregulated	downregulated	not altered	not altered	downregulated


Effects of MCMVwt and mutants on m138 targets at the surface of infected cells

















1/100

0

1/10

40-

20-

0

0

